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Abstract
Human fibroblast growth factor one (hFGF1) belongs to a family of 22 FGF members produced
by fibroblast cells. Cell signaling during physiological processes of angiogenesis and wound
healing occurs when hFGF1 binds to its receptor (FGFR). However, when heterogenous
homeostasis is not maintained, fibroblast cells exhibit excessive proliferation which can lead to a
myriad of cancers. smFRET is an ultrasensitive distant dependent (1-10 nm) technique capable
of resolving such heterogeneity in structural dynamics and binding affinities (Kd). Therefore, we
successfully designed and characterized fluorescently labeled hFGF1 tracers which span the
visible light region of the electromagnetic spectrum for use in smFRET. Fluorescent labeling was
achieved by utilizing the maleimide moiety of the dyes (Alexa Fluor, Cyanine and iFluor) to
conjugate to the cysteine residues via a thioether bond. We synthesized biologically active, and
site specifically fluorescently labeled hFGF1 mutants of F2C-hFGF1 (on the flexible N terminal
loop) and T79C-hFGF1 (on the rigid loop between β strand 7-8). The main findings showed that
the dye and protein required a certain degree of flexibility to obtain high labeling efficiency but
having too much flexibility caused low labeling efficiency because of entropic penalty during
conjugation. Ensemble and single molecule level characterization of the photophysical
parameters of ensemble QY, fluorescence lifetime and molecular brightness revealed that the
dyes properties depended on the rotational and vibrational degrees of freedom of the dye on the
protein, dye structure and degree of flexibility of the labeling site. Overall, we successfully
fluorescently labeled hFGF1 at specific sites and characterized its photophysical properties as
this information is critical in designing FRET assay.

Acknowledgements
I would like to thank my Lord and Savior Jesus Christ for giving me the strength to go through
graduate school and all the blessings in my life. I am very grateful for my advisor Prof. Colin
Heyes, for always encouraging me to keep working even through the many challenges of this
work and for his support throughout this journey. I am also grateful for Prof. Suresh Kumar for
allowing me to use his lab and for his collaborative input in this project. I am thankful to my
previous advisor from Rhodes University Prof Nelson Torto for his selflessness and invaluable
support throughout my academic career. To the Heyes lab, thank you guys for making the lab
experience fun. I also want to thank Mahsa Lotfi and Isabelle Niyonshuti for being my friends in
grad school and for always encouraging me. Lastly, I am thankful to my family and friends here
in the USA and from back home in Lesotho.

Table of Contents
I. Introduction ............................................................................................................................... 1
Human Fibroblast Growth Factors.................................................................................................. 1
The Role of Heparin as a Cofactor to FGF ..................................................................................... 4
Fibroblast Growth Factor Receptor ................................................................................................ 4
Interactions Between FGF and FGFR for Signaling....................................................................... 7
Signaling Pathways Triggered by Binding of FGF to it Receptor (FGFR) .................................... 9
Fibroblast Growth Factor Receptor (FGFR) Regulation .............................................................. 10
Clinical Significance of FGF/FGFR Signaling ............................................................................. 12
Fluorescence and Quenching ........................................................................................................ 17
Fluorescence Resonance Energy Transfer (FRET)....................................................................... 18
Photophysical Properties of Fluorescent Dyes ............................................................................. 21
Objective of the Project ................................................................................................................ 26
References ..................................................................................................................................... 28
II. Site-Specific Labeling and Functional Efficiencies of Human Fibroblast Growth Factor1 with a Range of Fluorescent Dyes in the Flexible N-Terminal Region and a Rigid β-turn
region ............................................................................................................................................ 37
Abstract ......................................................................................................................................... 37
Introduction ................................................................................................................................... 38
Materials and methods .................................................................................................................. 45
Results ........................................................................................................................................... 48
Discussion ..................................................................................................................................... 55
Conclusion .................................................................................................................................... 57
References ..................................................................................................................................... 64
III. Insights into How Labeling Position and Dye Structure Affects the Ensemble and Single
Molecule Properties of Fluorescently Labeled Human Acidic Fibroblast Growth Factor. . 72
Abstract ......................................................................................................................................... 72
Introduction ................................................................................................................................... 73
Materials and Methods .................................................................................................................. 78
Results ........................................................................................................................................... 87
Discussion ................................................................................................................................... 105

Conclusion .................................................................................................................................. 111
References ................................................................................................................................... 112
IV. Towards Designing smFRET Assays to Study the Regulation of FGF Binding to its
Receptor (FGFR) ...................................................................................................................... 131
Abstract ....................................................................................................................................... 131
Introduction ................................................................................................................................. 132
Materials and Methods ................................................................................................................ 136
Results ......................................................................................................................................... 138
Discussion ................................................................................................................................... 145
Conclusion .................................................................................................................................. 147
Future work ................................................................................................................................. 147
References ................................................................................................................................... 151
V. Conclusion............................................................................................................................. 154

I. Introduction
Human Fibroblast Growth Factors
Fibroblast growth factor (FGF) gene is divided into seven subfamilies (fig.1) which each
contain up to four members based on their biochemical similarities. [1, 2] In total, there are 22
FGF coding genes (FGF1-22) which are mainly found in the paracrine but also in the endocrine
and intracrine (fig.1). [2, 3] The location of all human FGF chromosomes is known except for
FGF16 while their roles are also mostly determined. [1] Chromosomes of human FGFs are
scattered throughout the genome which indicates that their generation is by duplication and
translocation. Further, location also determines clustering when certain FGFs are found on the
same region of the chromosome. For instance, FGF3, FGF4 and FGF19 are all located on
chromosome 11q13 and are separated by 40 kb and 10 kb respectively. [1] This clustering is
supportive evidence that the FGF gene expanded by duplication and translocation.
The role of FGF is to predominately act as a mitogen protein that stimulates the growth of
fibroblast cells, which are the most common cells of connective tissues in animals. [4] Cellular
growth is described as angiogenesis, which occurs through tumor growth, wound healing and
embryonic development. [5] The function of FGF is to regulate the response of the cell during
proliferation, differentiation and migration. Furthermore, the respective 22 ligands family
members of FGF bind their receptors (FGFR), with high affinity on the cell surface. [1, 6] In
addition, FGF requires an accessory molecule of heparin which enhances its binding to FGFR.
The family of FGFs can also be considered to be categorized into three subfamilies (fig.1) of
canonical (paracrine), hormonal (endocrine) and intracellular (intracrine). [7, 8] FGF1 is a
universal ligand, which can bind to four isoforms of FGFR. Canonical FGFs are highly specific
to fibroblast cells and bind their receptors and heparin with high affinity. Hormonal forms of
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FGFs require α-klotho co-receptor as they bind to FGFR with less affinity and are also expressed
in adult cells of the liver, intestines and bones. [7] Intracellular FGFs do not interact with FGFRs
but with other protein such as salt channels.
Most members of FGFs are secreted via the non-classical pathway of autocrine signaling
because they lack the N terminal signal peptide. [9] The mechanism of secretion has not been
fully elucidated but important transmembrane proteins involved are P40, S100A13 and Annexin
II. [10, 11] Briefly, FGF-1 homodimer (formed via a cys30-cys30 disulfide bond) binds to P40
and S100A13 to form a trimeric complex, which then binds to the rod, shaped Annexin II. The
tetrameric complex (FGF/P40/S1-00A13/Annexin II) is then secreted to the outside of the lipid
bilayer due to the ability of Annexin II to flip flop across the membrane. [12, 13] The mechanism
of FGF release is not exactly known but mutations in these chaperone proteins have shown to
block release of FGF. [14] Metals such as calcium and copper also play a key role in this
process. [15] Initiation for signaling [16] occurs via a symmetric dimerization of two FGFFGFR-Heparin complexes, which then triggers a myriad of pathways although there are
conflicting mechanisms that exist among researchers.
Structurally, all FGFs are in a β-trefoil topology as shown in fig.2 and they consist of 12
antiparallel β strands arranged in three copies of four β sheets. [16] Their molecular weight
varies from 17 to 34 kDa. There is a highly conserved region of 120 amino acids in all FGFs
while homology can vary between 16 and 65 %. For instance, FGF-1 has a 55 % homology to
FGF-2. The conserved regions are mainly in the β strands while variety exists in the loops. [16]
There are four cysteine residues present in the conserved region which are not involved in
disulfide bonding for the tertiary structure folding of FGF. [9] FGFs can be categorized as acidic
or basic depending on the most prominent types of isoelectric amino acids present.
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Figure 1. Classification human fibroblast growth factor (FGF) subfamilies. Relationship of
human FGF families by genetic evolution. There are 22 encoding genes arranged in 7
subfamilies categorized by biochemical similarities. Classification can also be canonical,
intracellular and endocrine which require their respective cofactors to carry out their biological
activities. Adapted with permission from reference 2 and copyright from Wiley.

Figure 2. The three-dimensional structure of human FGF1. FGF1 is arranged in beta barrel
topology of 12 antiparallel β-sheets. The amino (N) and carboxyl (C) termini are shown. Adapted
with permission from reference 16 and copyright from Elsevier.
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The Role of Heparin as a Cofactor to FGF
Heparin belongs to a family of glycosaminoglycans and they play a critical role in
dimerization of FGFR for signaling. [17] Defects in heparin biosynthesis leads to low FGF
signaling. [18] Heparin is a linear polymer of alternating glucoronate (Glu) and Nacetylglycosamine (GluNAc) monosaccharides. Modification of heparin by sulfonation and
epimerization forms HS, which contains a N-sulfonated domain (NS region) and an acetylated
domain (NA region). [19, 20] The NS region is created by N-deacetylation and sulfonation on
the first 10-20 units of GluNAc polymer, which then intersperses within the remaining NA
region. [19] FGFs can bind to heparin via their β1-β2 and β10-β12 strands while in FGF2 the
important amino acids for binding are N27, R120, and L1259. [21] Sucrose octasulfate (SOS) is
the analog of Heparin commonly used for invitro proliferation experiments. It can mimic heparin
and bind to FGF and FGFR. [22]

Fibroblast Growth Factor Receptor
Fibroblast growth factor receptor (FGFR) is one of the classes in a family of 20 receptor
tyrosine kinases (RTKs) in humans. [23, 24] The main function of RTK is to bind growth
factors, hormones and cytokines for the activation of signaling pathways to initiate growth and
maintain homeostasis. [25] The generic structure of all RTK contains an extracellular ligandbinding domain, a single transmembrane domain and an intracellular tyrosine kinase domain. For
FGFR specifically, it has three immunoglobin “Ig” like domains, labeled as D1-D3 on the
extracellular domain and an acid box (AB) linking D1 and D2 (fig.3). [16] The D3 domain is
followed by a transmembrane helix, which is followed by an intracellular tyrosine kinase
domain. FGF binds FGFR primarily on the D2, D2-D3 linker and D3 domains while secondary
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binding is confined only to D2. [16] Heparin only binds D2 and FGF but does not bind the AB,
D2-D3 linker or the D3 domain.

Figure 3. Schematic of FGFR. The extracellular domain has a D1, acid box, D2, D3, D2-D3
linker while the intracellular domain contains a tyrosine kinase domain. D1 and acid box are
involved in auto-inhibition and ligand binding occurs on D2 and D3 domains. There two
different isoforms of D3 (IIIb and IIIc). Adapted with permission from reference 16 and
copyright from Elsevier.
There are two conflicting symmetric and asymmetric “two end models” on the sequence
of events that lead to dimerization. The symmetric model [26, 27] indicates dimerization to be as
a result of contact between the two FGF-FGFR-heparin complexes specifically on the D2
domains (receptor-receptor contacts). There are no FGF-FGF contacts in this model. The
symmetric model spatial arrangement of the dimer and location of several interactions between
FGFR and FGF is shown in fig.4. [26] Molecular surface color scheme (fig.4, panel A) of FGFFGFR-heparin complexes clearly shows the symmetric interaction while binding sites on both
FGF and FGFR are shown in fig.4, panel B. Conversely, the asymmetric model [28] proposes
that heparin/heparin contacts bridge the two complexes however, the dimer is not symmetric
because heparin on one complex binds the D2 while on the second complex it only binds FGF.
Nevertheless, mutations in the secondary FGF receptor contacts only present in the symmetric
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model showed lack of heparin induced dimerization, which led to a consensus acceptance of the
symmetric model over the asymmetric. [28]

Figure 4. Symmetric two end dimerization model. Panel A) Molecular surface representation of
FGF-FGFR-heparin complex. The left is a sideview and the right is a 90° rotation of the complex
looking down. FGF-FGFR-heparin complex is formed when heparin (ball and stick) binds both
D2 (green) and FGF (orange) which then leads to dimerization with a second complex confined
only between D2-D2 contacts. There is also contacts between the D2-D3 linker (grey) and FGF
while receptor-receptor of this linkers is minimal. There are no D3 (cyan) domains or FGF-FGF
contacts involved in the formation of the dimer. Panel B) Locations of various interaction sites
on FGF and FGFR. The color scheme for FGF, D2 and D3 is similar as in fig.4, panel A. The
primary binding site (red) of FGF with the receptor is only on D2 and D3 while the heparin
binding site (blue) is only on the D2 and FGF. The secondary binding site of FGF (purple) is
below the D2 domain. Receptor-receptor interaction between the two FGF-FGFR-heparin for
dimerization is confined to the bottom of D2 domains (yellow). Adapted with permission from
reference 26 and copyright from Elsevier.
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Interactions Between FGF and FGFR for Signaling
An extensive detailed analysis of the domains and their interfaces was carried out by
Plotnivok and co-workers. [29] They showed that D1 is the largest domain at the N terminal site
of the receptor and consists of 108 amino acids arranged in a β barrel structure. For ligand
binding, D1 is not required; however, it is involved in autoinhibition of the receptor. The most
important domain is D2 because it is involved in both ligand-receptor (FGF-D2-heparin) and
receptor-receptor (D2-D2) binding during dimerization. [26, 29] D2 consists of all β sheets
(fig.5) and electrostatic interactions with the negatively charged sulfate heparin/heparin sulfate
comes from the positively charged residues of Lys 16, Lys 19, Lys 28, Lys 31, and Lys 33. [29]
Hydrophobic effects have also been shown to be present at the interface of FGF and D2 domain.
For instance, in the FGF2-FGFR2 complex, Tyr 24, Leu 140, Met 142 of FGF2 interacts via
hydrophobic binding with Ala 168 of FGFR2 (fig.6). [29] In addition, Leu 140, Tyr 103 and Asn
102 also hydrophobically interact with Pro 170 of the receptor. Hydrogen bonding also stabilizes
the FGF2-FGFR2 complex as Tyr 24 of FGF2 interacts with the backbone atoms of Leu 166 and
Ala 168 of D2. [29, 30] Furthermore, Tyr 102 of FGF2 also interacts with Ala 168 backbone.
For interactions between FGF and Heparin, Lys 26 and Lys 135 of FGF1 on the C terminal have
been found to be prominent. Residues on the D2-D3 linker also hydrogen bonds with FGF via
Arg 251 of FGF2 and the side chain of Asn 104 of FGFR2. The D3 domain is subject to
alternative splicing in βC‘-βE and βF-βG strands (fig.5) which gives rise to the 4 isoforms of
FGFR. [29] Moreover, the strands of βB'-βC are highly conserved since this is the location of
FGF binding via water mediated hydrogen bonding. Therefore, it is apparent that hydrogen
bonding, electrostatic interactions and hydrophobic effects are highly significant in stabilizing of
the FGF-FGFR complex.
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Figure 5. Ribbon diagram of FGF2-FGFR2. D2 and D3 domain are shown in green and cyan
respectively and both are all β strands. FGF1 is shown in orange and is also all β strands. The N
terminal is on the D2 domain while the C terminal is on the D3 domain. The gray is the D2-D3
linker while purple is the disordered βC‘-βE loop of D3 domain. Adapted with permission from
reference 29 and copyright from Elsevier.

Figure 6. Interactions between FGF2 and D2 of FGFR2 interface. FGF2 is colored in orange
while D2 is in green. There are hydrophobic interactions between Tyr 24, Leu 140, Met 142 of
FGF2 and Ala 168 of FGFR2. Leu 140, Tyr 103 and Asn 102 of FGF2 has hydrophobic
interactions with Pro 170 of the FGFR. Hydrogen bonding is also present between FGF2-FGFR2
complex as Tyr 24 of FGF2 interacts with the backbone atoms of Leu 166 and Ala 168 of D2.
Adapted with permission from reference 29 and copyright from Elsevier.
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Signaling Pathways Triggered by Binding of FGF to it Receptor (FGFR)
Dimerization of FGF-FGFR-Heparin complexes on the extracellular domain leads to
transphosphorylation of several tyrosine residues on the C terminal tail of the transmembrane
and kinase domain of FGFR. Phosphorylation triggers signaling of pathways such as
phosphoinositol (PLCγ), phosphatidylinositol-3-kinase (Pl3K/Akt) and Ras dependent mitogen
activated protein kinase (MAPK). [2, 31, 32] These pathways are denoted respectively as A, B
and C in fig.7. [32] The tyrosine residues that are phosphorylated are Tyr 463, 583, 587, 653,
654, 730, 766, which leads to recruitment of signaling proteins that bind at these residues to
create a signaling cascade in the different pathways. [27, 33] For instance, the prominent PLCγ
pathway involves binding of PLCγ to Tyr 766 which results in hydrolysis of phosphatidylinositol
4,5-biphosphate (PIP2) to two second messenger molecules of diacylglycerol (DAG) and inositol
1,4,5-triphosphate. The messengers help induce calcium release for subsequent signaling for the
cell to migrate. Ras depended on MAPK is another important pathway whereby adaptor protein
FGFR substrate 2 (FRS2) binds to the phosphorylated kinase domain site to recruit the Ras
protein through Grb2 and SOS for cell proliferation signaling. [34, 35] The Pl3K/Akt pathway is
important in cell survival as Gab 1 & 2 binds to the activated kinase domain to recruit PI3K
proteins. Additional pathways triggered by FGFR signaling are p90 ribosomal protein S6 kinase
2 (RSK2) and signal transducers and activators of transcription (STAT). [36, 37]
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Figure 7. Signaling pathways triggered by FGF-FGFR dimerization. Pathways denoted A, B
and C respectively are phosphoinositol (PLCγ), phosphatidylinositol-3-kinase (Pl3K/Akt) and
Ras dependent mitogen activated protein kinase (MAPK). The respective path-ways control
morphogenesis exhibited during cell migration, survival and proliferation Adapted with
permission from reference 32 and copyright from Company of Biologist.

Fibroblast Growth Factor Receptor (FGFR) Regulation
Deregulation of FGFR signaling is known to be involved in the cause of many cancer
types, including prostate, breast and gastric [38-40]. Excessive proliferation and signaling can
lead to overexpression of cells leading to these cancer types, hence there is a need for strict
regulation. [41, 42] There are several proposed mechanisms of regulation both on the
extracellular and intracellular domains of FGFR. For example, Chen and coworkers proposed
that the unphosphorylated intracellular part of the kinase domain contains a catalytic triad, which
creates a molecular brake to prevent interaction between the N and C lobe of the kinase domain.
[43] The triad consists of E565 (kinase hinge), N549 (loop between αc helix and β4 strand) and
K641 (β8 strand) which interact via hydrogen bonding to form the brake, which then causes
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autoinhibition of the signaling process. The researchers went further to show that upon
phosphorylation, the brake disengages to continue activation for signaling.
On the other hand, there are two main competing theories on the autoinhibitory events
that occur on the extracellular domain. One theory proposes that the AB swings down to bind the
Heparin site on D2 therefore preventing FGF from binding (fig.8, panel A). The reasoning for
this theory is based on the fact that AB is negatively charged while the heparin-binding site on
D2 is positively charged. In fact, there have been studies in support of this theory by Olsen and
Kalinina [44, 45] who showed through surface plasmon resonance and NMR respectively that
the presence of the D1 domain decreased the binding affinity of heparin on FGFR4. However, a
second theory by Kumar and Rutherford [46] indicates that AB binds to FGF instead of D2
preventing FGF from binding to the receptor (fig.8, panel B). The rationale is similar to that of
the first model in that FGF also contains the positively charged heparin site which can also bind
the negatively charged AB domain. Alternative splicing of exons encoding the C terminal on the
D3 domains are also involved in autoinhibition as they form different isoforms or delete the D1
or acid box which then regulates signaling. [47] These two conflicting models present an
opportunity to be resolved by single molecule detection fluorescence technique such as forster
resonance energy transfer (FRET) which will be explained below as well as in the objectives of
the project.
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Figure 8. Proposed models for the autoinhibition of FGFR. Panel A) In this model, the acid box
binds D2 domain on the heparin site preventing FGF from binding. Panel B) FGF binds the acid
box instead of the D2 Adapted with permission from reference 45 & 46 and copyright from
Elsevier.

Clinical Significance of FGF/FGFR Signaling
Cancer
Mutations on the KAL-2 gene that encodes for FGFR have been identified to cause
several cancers that include prostate, lung and breast. [48, 49] These gene mutations cause FGFR
to gain or lose (by overexpression of the protein) molecular function because of unregulated
proliferation of normal cells, which ultimately become malignant. The growth progression of
these malignant cells is further enhanced by sustained tumor promoters such as supply of
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nutrients, oxygen and hormones like estrogen. Convincing evidence for involvement of FGFR in
the progression of cancer has come from hematology. [50] It was observed that there was a
translocation of chromosome 8p11 into the N terminal of FGFR1 kinase domain that led to the
overexpression of the receptor in about 30 % of breast cancer patients. Furthermore, increased
expression of FGFR3 was also identified in translocation of chromosome t(4;14) in 15 % of
myeloma patients. The overexpression was caused by strong expression inducers of IgH. [51]
FGFR targeted therapy was shown to be effective by inhibiting pathways triggered by
phosphorylation of tyrosine kinase domain in people with breast and myeloma cancers. [52] In
addition to chromosomal translocation, point mutations were also identified to result in cancers.
For instance, human urothelial cell carcinoma (UCC), mutation on the FGFR3 ligand-binding
domain caused constitutive or increased activation of the receptor. [53] Point mutations S249C
and Y373C on the ligand-binding and transmembrane domains respectively were implicated to
form additional disulphide bridges, which constitutively increased dimerization and subsequently
enhanced activation of the receptor. [53, 54] Further point mutations of K652 on the kinase
domain resulted in increased binding of adaptor proteins, which then disengaged the
autoinhibition process that regulated the domain. Uterine cancer also resulted from point
mutations S252W and P253R on the FGFR2 ligand-binding domain. [27] There have also been
cases whereby FGFR has been shown to cause loss of function and suppress cancer, although
further research needs to be carried out to quantify the effects.

Skeletal disorders
Skeletal dysplasia’s have been linked to point mutations in FGFR1-3 due to impairment
in the development of cranial, skeletal muscles and bones [55]. It has been identified that
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FGFR1-3 is responsible for syndromes of pfeifer, apert and achodroplasia respectively in mice
whereby in three cases the general phenotype defects are seen on feet and limbs. [56] The point
mutations identified to be responsible in FGFR1 are P252R while FGFR2 has mutations of
P253R, S25W. FGFR3 exhibits G346E, G375C and G380R mutations. All the mutations on the
receptor are common on the extracellular domains and result in gain of function. [38, 50]
Moreover, point mutations on D3 of FGFR2 are known to cause severe forms of dwarfism. In
these mutations, one of the two highly conserved cysteine residues on the D3 domain is changed
and this enhances dimerization of ligand receptor interactions due to an additional disulphide
bond that is formed. D2-D3 linker mutations on amino acids such as S252 and Pro253 are also
responsible for Apert syndrome. [57] Kallmann syndrome is another disorder caused by
mutations in KAL-1 gene, which encodes for FGFR1 and the mutations create defects in
olfactory bulb development, which is important for smelling and hearing. [48] It is evident that
lack of regulation of FGFR signaling can create a gain of function, which then causes a myriad
of cancers and skeletal disorders. It has become critical to understand the autoinhibition
mechanism that regulates FGFR signaling, which will be important in the development of anticancer therapies targeting FGFR.

Therapies Using FGF for Treatments
The biological function of FGF in various physiological process triggered by signaling
has led to its use in a myriad of therapies for human diseases such as cancer, dwarfism and
Kallmann syndrome. [16] There are many potential therapies using FGF, but only predominant
ones will be explored. FGF1 has been explored for potential use in cardiovascular disorders
whereby phase I trials showed that it improved the growth and proliferation of the collateral
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artery during coronary artery bypass surgeries. [16] In addition, FGF1 also improved cell growth
in ischaemia patients as phase I of the trial showed reduced need for amputation in patients. [58]
Spinal cord regeneration was also found to improve when FGF1 was administered to rats as well
as motor function recovery in a 6 month only patient. [16] In recent therapy developments, FGF1
has also proven to be a candidate for use in type 3 diabetes mellitus as it can be used to regulate
glucose levels. [59]
In wound healing, the best candidates in the FGF family have been FGF2, FGF7 and
FGF10 which have also been recommended by the US Wound Healing Society and European
Wound Management Association. [60] FGF2 has been the most widely used for wound healing.
For instance, patients with second degree burns showed faster granulation of tissue regeneration
of the epidermis when treated with formulations containing this protein. [60, 61] In 2004, the
company Amgen released a FGF7 formulation (trade name is kepivance) capable of regenerating
the skin membrane lining during mucositis caused by chemotherapy in leukemia patients. [60]
FGF10 formulations were also found to increase healing rate of chronic venous leg ulcers.
Other therapies include the use of FGF21 which plays a critical role in the regulation of glucose
and lipid metabolism in the liver. The regulation is through the PLC-PPAR-adiponectin signaling
pathways whereby using this protein can treat type 2 diabetes and obesity. [60, 62] In addition,
its presence in the endocrine system where its secreted has also been shown to aid to have aid in
protecting the heart during corona artery cardiovascular disease. [62] Recent area of research has
been incorporation of FGFs particularly FGF1 into polymers such as hydrogels for their release
during wound healing. [63] Nanoparticles such as liposomes and micelles are also being
explored as delivery agents of FGFs in the bloodstream. [64]
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Antitumor Inhibitors Targeting FGFR
The clinical significance of FGFR is that its mutations and deregulation cause various
types of cancers as already discussed. Hence, there are therapies and drug inhibitors utilized to
target FGFR signaling. For instances, small molecule inhibitors of dovitinib, KI23057 and
AZD4547 have been explored in clinical trials in cancer treatments. [65] Interact of with FGFR
with inhibitors can be covalent which irreversible of non-covalent which is reversible. [66, 67]
The inhibitors typically target the kinase domain of FGFR by selectively binding certain amino
acids residues which high affinity. [68] For example, AZD4547 interact via the ATP pocket of
FGFR1 forming hydrogen bonding with Asp641 residue thus inhibiting the receptor. [68]
Monoclonal antibodies such as kn134 (FGF8b-targeting neutralizing antibody) have shown
capability to be used for blocking signaling pathways in breast cancer which are triggered by
FGF ligands. [69] Other antibodies include Gp369 which is a FGFR2 IIIb-specific blocking
antibody which reduces the proliferation of cancer related to gene mutations and gain of function
by the FGFR2 gene. [60] In addition, there are also FGF “ligand traps” which are immunoglobin
Fc fragments that compete with FGF binding to FGFR ligand binding domain in order to inhibit
signaling. [70] Fp-1039 is one such example which competes with FGF2 on binding FGFR1
ligand binding domain to minimize proliferation. [71] These traps are particularly efficient as
cancer therapies which can minimize overexpression of cell proliferation in cancer patients.
In summary, it is evident that the clinical significance of FGF/FGFR signaling requires extensive
research both in understanding the pathological implications and potential therapies. As a result,
the phenomenon of fluorescence and its various techniques, have proven to be the best candidate
to use for obtaining biochemical information relating to FGF/FGFR interactions.
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Fluorescence and Quenching
Fluorescence is described as the emission of light by molecules that have been excited by
photons. As shown in the Jablonski plot (fig. 9) [72], the incident photons first strikes the
electrons resulting in their absorption of photons (hѵabs), which then excites them from the
ground electronic state (S0) to the higher excited electronic state (S1). [73] Once the electrons are
excited, they will relax back down initially to the zero vibrational energy level of S1 by internal
conversion (IC) and then to the ground state (S0) in the form of radiation (hѵem). The latter
radiative relaxation of spin allowed S1→S0 transition is the one called fluorescence and can
occur in the time frame of femtoseconds (10-15 s) to picoseconds (10-12 s). [72, 74, 75] However,
compared to absorption, fluorescence takes place at longer wavelengths as described by the
stokes shift because some of the absorbed energy can get lost in various forms such as
intersystem crossing and phosphorescence. Intersystem crossing occurs when an excited singlet
state electron in the S1 electronic state changes its spin to the triplet state. [73] Then when the
electrons relax back from the excited triplet state (T1) to the ground singlet state (S0) the
phenomenon of phosphorescence will occur. Phosphorescence is radiative but it takes a longer
time (10-3 s) than fluorescence because the transition of T1→S0 is spin forbidden. [72, 75]
Quenching occurs when the lifetime of the excited state is shortened by the presence of another
species. Quenching can be desired such as when energy or electronic transfer occurs, or it can be
undesired when it decreases the quantum yield of a photochemical process. [75] For instance,
quenchers such as oxygen can be undesired because they normally decrease quantum yields.
However, quenching from energy transfer can be desirable as molecular interactions can be
studied. This quenching phenomenon is called fluorescence resonance energy transfer (FRET).
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Figure 9. Jablonski plot. The plot describes that photons which absorb light energy (hѵabs) from
the ground state (S0) to higher excited states can undergo several processes such as fluorescence.
Fluorescence occurs the excited photons in from S1 energy level relax back down to the ground
state in the form of light energy (hѵem). Adapted with permission from reference 72 and
copyright from the author.

Fluorescence Resonance Energy Transfer (FRET)
FRET occurs when a fluorescent donor species can transfer its energy non radioactively
to another fluorescent acceptor species (fig.10). [76, 77] The fluorescent donor is excited first by
an external laser source while the non-radiative energy is transferred to the acceptor. During
energy transfer, the fluorescence of the donor will decrease while that of the acceptor increases.
The distance range for this phenomenon to occur is within 100 Å (10 nm) and there has to be an
overlap between the absorption spectrum of the donor and emission of the acceptor for FRET to
occur (fig. 11). [78, 79] These factors are important in FRET as the overlap determines FRET
efficiency, which directly depends on the distance of the two species. FRET efficiency is defined
by E = R06/ R06 + r6 whereby E is the energy transferred, r is the distance between the dye
partners and R0 is the forster distance which is the distance at which the transfer is at 50 % as
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shown in fig. 12. [78] Forster distance is a constant for each dye pair and is described by R06 =
(9000×Q0×(ln10)×κ2×J)/128×π5×n4×NA) which is affected by the orientation of dipole moments
(κ2) of the molecules, quantum yield (Qo) of the donor in the absence of the acceptor, the
refractive index (η) of the medium, the spectral integral overlap (J) and Avogadro’s number
(NA). [73, 74] The strong dependence of energy transfer on distance (r) means that by labeling
biomolecule partners with respective fluorescent donor and receptor dyes, structural interactions
between them can be studied. For the purpose of our study, we can utilize this technique by
labeling FGF and FGFR domains involved in each model and then monitor the FRET efficiency.
This will shed light on which domains are in close proximity (Kd values) and subsequently which
model of FGFR autoinhibition is likely possible. FRET has the main advantage of high
sensitivity since it requires sample concentration in the nM range. [80] Moreover, fluorescent
labels can be easily attached to protein partners of interest.
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Figure 10. Schematic of Forster Resonance Energy Transfer (FRET). Panel A) Binding partners
labelled with donor (CFP) and acceptor (Venus) exhibit FRET when they are close to each other
(< 10nm). Panel B) FRET also occurs when dipoles are in the same orientation. Adapted with
permission from reference 79 and copyright from Springer Nature.

Figure 11. Spectral overlap required between the donor and acceptor for FRET to occur. On the
left, FRET does not occur because the spectra of the donor and emission of the acceptor do not
overlap as they do on the right side of the spectra. Adapted with permission from reference 79
and copyright from Springer Nature.
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Figure 12. Dependence of FRET efficiency on distance. The graph shows that FRET efficiency
is directly dependent on distance and the forster distance is when 50 % of the energy can still be
transferred between donor and acceptor. Adapted from reference 78 from an open access
website.

Photophysical Properties of Fluorescent Dyes
Reactive fluorescent dyes have widely been used to modify amino acids in proteins for
applications using FRET. There is a large variety of fluorescent dyes with varying size, charge
and structure. However, a suitable dye for applications in FRET assays should exhibit the
following properties: high molecular brightness, high extinction coefficient, lifetime in
nanoseconds and high quantum yield. [81] Maleimide dyes exhibit these properties are therefore
commonly utilized for protein labelling because they also contain an imide functional group,
which can react with a sulfur of a cysteine residue to form a strong thiol ether bond. [82] The
cysteine used for labelling can be endogenous or site directed on the protein. Maleimide dyes can
act as both donors and acceptors between protein partners for FRET assays and the scheme in
fig. 13 [83] shows the interaction of maleimide dyes with proteins. Therefore, for our study, FGF
and FGFR domains will be labelled with maleimide dyes for development of FRET assays.
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Maleimide
Reagent

Sulfhydryl
on Protein

Stable Conjugate
(Thioether Bond)

Figure 13. Thiol bond formed between maleimide dyes and proteins. All maleimide dyes contain
the function imide group while “R” denotes different substituents of different charges, structures
and sizes. “P” denotes protein and the condition for thioether bond formation is pH 6.5-7.5.
Adapted from reference 83 from an open access website.

Rhodamine based Alexa Fluor Series
Rhodamine dyes are derivatives of xanthene organic molecules which are intensely
colored and absorb in the visible light region of the electromagnetic spectrum. [84, 85] In single
molecule detection, the most commonly used dyes which belong to the rhodamine family are
Alexa Fluor (AF) (trade name) series from Thermo Fischer Scientific. [86] There are a wide
range of these dyes, but fig.14 only shows the ones used in our experiments which are AF488,
AF546, AF595. AF647 is in the same series although it belongs in the carbocyanine based dyes.
These dyes were chosen because they can act as FRET pairs such as AF488 (donor) and AF594
(acceptor). [87] Alexa Fluor dyes contain sulfonates moieties which make them highly water
soluble thus reducing tendency to aggregate even at high concentration in millimolar (mM)
range. [86] Overall, substituents can enhance the photophysical stability of the dyes which is of
key importance for single molecule detection. They can cause the dyes to vary in charge,
hydrophobicity, absorption (λa), emission (λe), extinction coefficients (ꜫ), quantum yield (QY)
and lifetimes. [86] For instance, both AF488 and AF546 are rhodamine based however, they
absorb at 490 nm (λe = 525 nm) and 556 nm (λe = 573 nm) respectively. In addition, AF488 has
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QY of 0.92 while AF546 has QY of 0.79. This is due to the variation in substituents as can be
seen in fig 14.
In summary, AF series have excellent properties of high brightness and photostability.
They have strong absorption and coefficients which enable maximal excitation and subsequently
emission of fluorescence. [86, 88] Fluorescence is commonly retained during bioconjugation
although, it can be quenched. AF dyes are also highly soluble in water and are readily reactive
over a wide range of pH which causes the absorptivity to be insensitive to changes in the
aqueous media. They also have highly differentiated spectra which gives a variety of options
when selecting FRET pairs. Their FRET efficiency is also very high with forster distance (Ro)
recorded up to 84 angstrom. [86]

Carbocyanine Based Cyanine Series
Cyanine dyes are also highly popular in single molecule detection and are made by the
company of Lumiprobe. [89] They have characteristics of two heterocyclic nitrogens being
connected by a polymethine chain with an odd number of carbons. The length of the chain
affects the absorption on the visible light region of the electromagnetic spectrum [88, 90]. In
fig.14, CY3 has a polymethine chain with three carbons (trimethine) and absorbs at 555 nm (λe =
570 nm) while CY5 is pentamethine which absorbs at 646 nm (λe = 662 nm). The polymethine
chain can rotate and twist thus making the dyes highly flexible however, this tends to cause
quenching of fluorescence in free dyes. [91, 92] Decrease in fluorescence is because the
polymethine undergoes photoisomerization from the trans isomer in the ground state to the less
fluorescent cis isomer occurring in the excited state. Relaxation from the trans state is fluorescent
while the cis isomer is less fluorescent. [88] As a result, this causes cyanine dyes to have less
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fluorescence than their counterparts such as AF dyes. However, cyanines dyes are still widely
used since their fluorescence increases when bound to biomolecules. This is because the dyes are
less flexible and there is also reduced rotation and twisting which favors the more fluorescent
trans isomer. CY3B is not affected by photoisomerization because it is a rigid form on cyanine
whereby the polymethine does not undergo twisting and rotation. [93] Therefore, it tends to
retain its fluorescence whether in the free dye state or when bound to biomolecules.
Factors which also affect cyanine dyes besides photoisomerization are viscosity,
quenchers and proximity to biomolecules during conjugation [94]. Molecules such as glycerol
tend to increase viscosity of the reaction solution during bioconjugation which reduces the rate of
photoisomerization towards the less fluorescent cis isomer hence, favoring the more fluorescent
trans isomer. [92, 94] In a similar manner, proximity of the dye to the biomolecule due to
conjugation also makes the probe to be more rigid thus, favoring the fluorescent trans isomer.
Cyanine dyes are also sensitive to quenchers such oxygen which favors the less fluorescent
triplet state. Reducing and oxidizing systems (ROXS) such as trolox are commonly used to
recover the triple state and reduce blinking. [88] Overall, reducing the rate of photoisomerization
leads to increased fluorescence which still makes these dyes very useful in single molecule
detection.

24

AF488

AF546

AF594

λa = 490 nm, λe = 525 nm

λa = 556 nm, λe = 573 nm
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λa = 650 nm, λe = 665 nm
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=

Maleimide moiety

Figure 14. Fluorescent probes used for labeling FGF and FGFR. Structures, absorbance (λa) and
emission (λe) are shown for each dye as provided by the vendor. Alexa Fluor (AF), Cyanine
(CY) and iFluor (iF) series used for labeling. The structure of iF647 is not known due to
propriety. Structures drawn using Chemdraw.
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Objective of the Project
The main objective of this study is to investigate how labeling at specific sites of F2C and
T79C on hFGF1, affects the ensemble and single molecule photophysical properties of the
structurally different classes of probes. Fluorescent labeling of hFGF1 was achieved by the use
of probes that have the maleimide moiety which, can specifically bind to the cysteine residues of
the proteins. hFGF1 has three native cysteine residues however, they are buried within the β
trefoil barrel of the protein and were found to not fluorescently label with dyes. To overcome this
challenge, mutants were synthesized at the flexible N terminal loop region of F2C (Phe to Cys)
and the more rigid region of T79C (Thr to Cys) that are exposed to the solvent for labeling.
Probes used were Alexa Fluor, Cyanine and iFluor series and were a combination of rigid and
flexible structures which, exhibit different and/or similar photophysical properties depending on
the site of labeling on the protein. Photophysical parameters investigated on both labeled F2ChFGF1 and T79C-hFGF1 were ensemble fluorescence quantum yield (QY), molecular brightness
(Ꜫ) and fluorescence lifetimes. Molecular brightness was extracted using two single molecule
approaches of fluorescence correlation spectroscopy (FCS) and photon counting histogram
(PCH). A combination of these photophysics parameters allowed us to quantify the degree of
static vs dynamic quenching of dye fluorescence. In addition, it also helped us to determine how
the dye behavior affect the ability to detect single molecules using fluorescence and ultimately
quantify studies such as FRET efficiency.
Our findings revealed that the photophysical parameters of ensemble QY, molecular
brightness and fluorescence lifetimes behaved in unpredictable ways as free dyes vs when
conjugated to the proteins. A seemingly poor ensemble fluorescence quantum yield can still lead
to single molecule detection or vice versa. For instance, rigid structured rhodamine free dye of
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AF488 had an ensemble QY of 75.97 ± 0.54 % that was quenched significantly on F2C-hFGF1AF488 mutants to 9.73 ± 0.05%. However, at the single molecule level, F2C-hFGF1-AF488 and
AF488 could be detected with respective molecular brightness of ꜪFCS = 26951 cpms and ꜪFCS =
17996 cpms. Further, lifetime results showed that F2C-hFGF1-AF488 and AF488 had similar
lifetimes of 3.10 ns and 4.11 ns respectively. Conversely, a seemingly quenched ensemble QY of
free dyes exhibited a large protein induced fluorescence enhancement at single molecule level
upon being conjugated to the protein. For example, flexible cyanine dye of CY3 had an ensemble
QY of 1.85 ± 0.45 % that increased drastically to 12.57 ± 0.21 % on F2C-hFGF1-CY3. In
addition, it had respective molecular brightness and lifetimes of ꜪFCS = 3668 cpms and 0.31 ns
that also increased significantly to ꜪFCS = 12172 cpms and 1.10 ns when bound to F2C-hFGF1. A
similar behavior was also observed on the rigid fluorescently labeled site of T79C-hFGF1-CY3
that had ensemble QY, molecular brightness and lifetimes of 18.27 ± 2.67 %, 11635 cpms and
1.23 ns respectively. Overall, these results indicated that the photophysics behaviors are affected
by the structure of the dyes, changes in rotational and vibrational degrees of freedom of the dye
and the degree of flexibility of the labeling site. Local environment such as neighboring aromatic
amino acids that can quench the dyes also play a critical role in the photophysics of the dyes.
Most importantly, ensemble studies do not always correlate to single molecule studies while
trolox did not significantly enhance the photostability of the dyes compared to no trolox studies.
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II. Site-Specific Labeling and Functional Efficiencies of Human Fibroblast Growth Factor1 with a Range of Fluorescent Dyes in the Flexible N-Terminal Region and a Rigid β-turn
region
Mamello Mohale, Ravi Kumar Gundampati, Suresh Thallapuranam and Colin D Heyes
Abstract
Human fibroblast growth factor 1 (hFGF1) binding to its receptor and heparin play critical roles
in cell proliferation, angiogenesis and wound healing but is also implicated in cancer.
Fluorescence imaging is a powerful approach to study such protein interactions, but it is not
always obvious if the site chosen will be efficiently labeled, often relying on trial-and-error. To
provide a more systematic approach towards an efficient site-specific labeling strategy, we
labeled two structurally distinct regions of the protein – the flexible N-terminus and a rigid loop.
Several dyes were chosen to cover the visible region and to investigate how the structure of the
dye affects the labeling efficiency. Either the protein labeling site or the dye needs to have some
flexibility, but that having flexibility in both results in a significant decrease in labeling
efficiency. We hypothesize that this is due to the entropic penalty associated with the
bioconjugation of highly flexible species. Conversely, too much rigidity in both can result in
dye-protein interactions that can aggregate the protein. Importantly, site-specifically labeling
hFGF1 in these regions maintained biological activity. These results should be applicable to
other proteins by considering the flexibility of both the protein labeling site and the dye structure.

Key words: Human fibroblast growth factor 1 (hFGF1), Site-Directed Mutation, Site-specific
labeling, Dye Labeling, Bioactivity, Fluorescence spectroscopy.
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Introduction
Human fibroblast growth factor 1 (hFGF1) is a mitogen protein that stimulates the
growth of fibroblast cells in connective tissues. [1, 2] The physiological function of hFGF1 is to
regulate cellular response during proliferation, angiogenesis, differentiation and migration. [3-5]
hFGF1 binds with high affinity to its extracellular tyrosine kinase receptor, FGFR, to trigger
signaling pathways such as phosphoinositol (PLCγ), phosphatidylinositol-3-kinase (Pl3K/Akt)
and ras-dependent mitogen activated protein kinase (MAPK). [6, 7] While there are 22 family
members of FGF categorized into three subfamilies of canonical, hormonal and intracellular,
hFGF1 is a universal ligand that can bind to all four isoforms of FGFR. [8-10] In addition,
hFGF1 requires an accessory molecule of heparin which enhances its binding to the receptor.
[11] The consensus for cell signaling events are described by the “symmetric model” which
involves dimerization between two FGF-FGFR-heparin complexes whereby FGF specifically
binds to the D2 domains of FGFR. [12-14] These dimerization contacts are receptor-receptor
confined since there are no FGF-FGF contacts in this model. [15]
The binding of hFGF1 to its receptor needs to be regulated so that homeostasis can be
maintained. Conversely, deregulation of this binding during signaling has been implicated to
predominately contribute to pathological conditions such as cancer, skeletal disorders and
diabetes. [3, 16-18] hFGF1 has also been shown to be a suitable candidate for therapies targeting
cancer, wound healing, renal diseases and glucose homeostasis. [19] Thus, there is a need to
employ biophysical techniques that are both selective and sensitive in nature in order to study the
role of FGF in pathology and therapeutic treatments.
Fluorescence microscopy is a highly sensitive method to study protein localization,
interactions and structure in physiological environments. It can be used to determine in which
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sub-cellular compartments proteins localize and/or interact. For instance, multicolor imaging of
Cy3-labeled hFGF1 in fixed Hela cells showed endocytosis and colocalization with FGFR4 in
juxtanuclear compartments prior to recycling. [20] Fluorescence microscopy has been
extensively employed at the single molecule level for studying conformational heterogeneity [21,
22], structural dynamics [23] and can also be performed in live cells. [24-28] Single Molecule
microscopy also allows for super-resolution imaging and, recently FGFR networks were imaged
on the plasma membrane using DNA-assisted fluorescence labeling (DNA-PAINT).[29]
While normal fluorescence imaging can overcome low labeling efficiencies or partial
inactivation of the protein by increasing the concentration of the labeled species – up to the point
where background staining becomes an issue, fluorescence at the single molecule level requires
high labeling efficiencies and minimal effect on function. [30, 31] Therefore, the choice of
fluorescent probe and/or labeling site during the bioconjugation step is very crucial and usually
requires a combination of educated guesses and trial-and-error. [28] Fluorescent probes can be
charged/neutral, rigid/flexible, bulky/small, hydrophobic/hydrophilic and the labeling efficiency
can vary depending on the accessibility of the protein labeling location to the dye. Once the
protein is labeled, loss of bioactivity can occur, which is usually due to either the probe
interfering with the binding/active site on the protein or due to physicochemical interactions
between the probe and protein, potentially causing its unfolding and/or aggregation. [30, 32]
Denaturing of the protein is particularly common during labeling of small molecular weight
proteins. [28, 33] As a result, it is paramount to carefully design and fully characterize sitespecific attachment of probes to the protein to maximize labeling efficiency and minimize loss of
bioactivity.
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A range of fluorescent probes have been used to label proteins, including producing
fusion proteins with green fluorescent protein (GFP) or its analogues. [34] The ability for these
fluorescent probes to be produced by the cell already attached to the protein of interest is a very
powerful approach, but they have limitations due to their relatively large size of ~ 27 kDa, which
can influence the structure and/or dynamics of the protein, particularly for small proteins, [35] as
well as their relatively low photostability. [36] Quantum Dots are also often used due to their
high photostability, ease of color tuning and multiplexing abilities, but have pitfalls such as even
larger sizes, multivalency, toxicity effects and blinking. [37] Organic dyes have gained
widespread use because they often mitigate the disadvantages of both fluorescent proteins and
quantum dots with regards to their small size (~ 1 kDa), together with high brightness, moderate
photostability, and control over labeling valency.[38] They are also commercially available to
span the entire visible light region of the electromagnetic spectrum. One issue of some organic
dyes is that they can have limited solubility in aqueous solvents, particularly for larger/redder
dyes. [39] However, this limitation is often overcome via sulfonation of the aromatic rings that
usually comprise their structure. It must be highlighted that this modification introduces charges
that may interact with the protein’s charged amino acids, and so care must be taken when
choosing this option. In single molecule experiments, Alexa Fluor® (a trademark of Life
Technologies Corporation) and Cy® (a trademark of GE Healthcare) fluorescent dyes are the
most widely used probes because of their excellent optical properties, although newer/alternative
dyes are being developed all the time, some of which are structurally identical to Alexa Fluor®
or Cy®, and some of which have proprietary structures.
There are several bioconjugation chemistries employed to attach fluorescent dyes to
proteins, the most common of which is using succinimidyl-ester functionalized probes which
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bind to primary amines. [40] Since all proteins contain at least one primary amine (N-terminus),
almost all proteins contain multiple lysine groups. Mammalian proteins have, on average, 7.2 %
lysine residues, [41, 42] which makes this chemistry rather universal. Due to the multiple
potential labeling sites, it is possible to have a very highly fluorescent labeled protein by adding
multiple dyes per protein. However, this advantage can also be a disadvantage with having
limited control of the labeling position. The high degree of labeling can lead to protein
precipitation, [43] self-quenching of the probe [44, 45] as well as lack of control over avoiding
the active site, which can lead to inactivation of the protein. [46] Maleimide-functionalized dyes
have become a more specific alternative approach, since the maleimide moiety reacts with the
thiol group of the protein’s cysteine residues to form a strong thioether covalent bond. [47, 48]
Since there is a much lower occurrence of cysteine residues in mammalian proteins (3.3 %),
more control over the labeling site can be achieved. [49, 50] Moreover, cysteines are usually
either buried into the hydrophobic protein core or are tied together in disulfide bonds, reducing
their ability to be labeled even further. Due to these reasons, cysteines are usually not found on
the protein surface or in the active site, unlike lysine, and thus they can often be mutated away
without major loss of function. [42] Thus, it is very common that a cysteine residue can be
introduced via site-directed mutagenesis without affecting the structure and function of the
protein, although this must always be experimentally verified. This is commonly employed when
the dye needs to be placed at a specific site on the protein for assays that involve structurefunction-binding studies to be performed, such as using Fluorescence Resonance Energy
Transfer (FRET) to extract distances between residues – whether on the same [22, 51] protein or
on different proteins upon binding. [52]
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The hFGF1 used in our studies has 141 amino acids (~ 17 kDa) arranged in a β-trefoil
topology. [53, 54] It has three native cysteines at residues 17, 84 and 118, which are in their
reduced state. [55, 56] However, these cysteines are buried within the hydrophobic core of the
protein, and do not fluorescently label. [57] It has been reported that removing these cysteines
affected proper folding, and thus reduced activity. [56, 58] Thus, this led to a need to carefully
develop mutants for site specific labeling by introducing a cysteine residue away from the active
site but with good accessibility to the dyes, and to ensure that these mutated/labeled proteins
remained active. Here, we label the protein at residue 2 (via a Phe-to-Cys mutation) and residue
79 (via a Thr-to-Cys mutation). Residue 2 is located in a highly unstructured and flexible region,
[57] while T79C is located on a β turn between sheets 7 and 8 (Fig. 1A) in a more structured
region. [59-61] Both these residues are exposed to the solvent, which should allow accessibility
to the probe, but not in the region where the receptor and heparin binds, which are both required
for bioactivity (Fig. 1B). [61] A previous report showed that residue 2 could be efficiently
labeled with the blue-emitting alkyl halide-functionalized dye, monobromobimane (mBBr) but
not with 5-bromomethyl fluorescein (BrF).[57] A tentative explanation for this difference was
postulated based on the size of the dye, but this was not fully investigated.
Our results show that the labeling efficiency of the dyes to each of these residues
depended strongly on the flexibility of the dye. More rigid dyes, such as the Alexa Fluor series,
showed high labeling efficiencies (up to 80 %) at the more flexible residue 2, while the more
flexible dyes, such as cyanine, showed very low labeling efficiencies at this same residue.
Conversely, more flexible dyes were able to label the rigid residue 79 with moderately high
efficiency (50-60%), while the more rigid Alexa Fluor dyes were not able to label this position
without causing aggregation of the protein. In our studies, the size of the dye appeared to play
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less of a role than the flexibility since red dyes and blue dyes of similar flexibilities showed
similar labeling efficiencies. We hypothesize that entropy plays more of a role than the size of
the dye when flexible regions of the protein are to be labeled. Conversely, too much rigidity in
both the dye and the protein site (residue 79) can result in dye-protein interactions that can
aggregate the protein, although this can be mitigated through dye solvation (e.g., via
sulfonation). Importantly, the presence of these probes on either region of the protein maintained
most of their biological activity since the sites were chosen to be away from the active/binding
site.
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Figure 1. Ribbon structure of acidic hFGF1 complexed with ectodomain of FGFR2 and heparin.
Color coding and site directed mutagenesis from the original structures was carried out using
pymol. A) Structure of hFGF1 (blue, PDB ID: 3OJM) showing the positions of F2C and T79C
mutants (cysteines are shown in yellow as sticks). hFG1 has a trefoil topology of 12 antiparallel
β strands. F2C mutant is on the unstructured N terminal segment and T79C mutant is on a bend
between β strand 7 and 8. B) hFGF1 (blue) complexed with heparin (sticks) and FGFR (D2 and
D3 domains are shown in green and red respectively, (PDB ID: 1E0O)). The complex structure
shows that the F2C and T79C on hFGF1 are facing away from the heparin and FGFR binding
sites.
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Materials and methods
Reagents
Quikchange XL kit for site directed mutagenesis of hFGF1 was obtained from Agilent
Technologies, (Santa Clara, CA, USA) while the DNA plasmid isolation was from Qiagen
(Germantown, MD, USA). Primers were from IDT DNA Technologies (Coralville, IA, USA).
Competent cells of DH5α and BL21(DES) were purchased from Novagen (Madison, WI, USA).
Bacteriological premixed Luria Broth (LB) agar and broth were acquired from EMD Millipore
(Burlington, MA, USA). Heparin-Sepharose resin and Cyanine 3B were purchased from GE
Healthcare (Chicago, IL, USA). Ampicillin, Isopropylthio-β-D-galactoside (IPTG), glass slides
and protein purification buffer salts of NaCl, (NH4)(SO4), Na2HPO4 and NaH2PO4 were from
VWR (Radnor, PA, USA). Biogel-P6 was obtained from Biorad (Hercules, CA, USA). Alexa
Fluor maleimide dyes, prestained standard protein ladder, Dulbecco's Modified Essential
Medium (DMEM) media, new born calf serum (NCS), L-glutamine and penicillin-streptomycin
were from Thermo Fisher Scientific (Waltham, MA, USA). NIH-3T3 mouse embryonic
fibroblast cells were obtained from ATCC (Manassas, VA, USA). CellTiter-Glo® luminescent
cell viability assay was from Promega, Madison, WI. Cyanine maleimide dyes with the
exception of Cyanine 3B were acquired from Lumiprobe Corporation (Hunt Valley, MD, USA).
The iFluor maleimide dye was purchased from AAT Bioquest (Sunnyvale, CA, USA). Glycerol
was purchased from Sigma Aldrich (St Louis, MO)

Cloning, overexpression and purification of hFGF1 wildtype and mutants
A truncated form of acidic hFGF1 (residues 15-154) without the first 14 amino acids on
the N-terminus was used. The truncated segment of the protein has been shown in literature to
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not affect the biological activity of hFGF1. [54, 56] For our experiments, mutants F2C and T79C
on hFGF1 are numbered to the sequence of this truncated form of 141 amino acids. The wildtype
DNA of WT-hFGF1 was cloned in vector pET020b, and the plasmid was used as a template for
site directed mutagenesis. Primers were designed following a protocol provided by QuikChange
II XL site directed mutagenesis kit vendor. Plasmids were transformed into DH5α cells, grown
on LB agar and isolated using Qiagen kit. DNA sequence of the isolated plasmid was confirmed
at a sequencing facility located in Molecular Resource Laboratory, University of Arkansas for
Medical Sciences, Little Rock, AR. After confirmation of the sequence, the plasmid was
transformed into BL-21 (DE3) E.coli cultured cells in lysogenic broth containing 10 %
ampicillin and IPTG. Overexpression was by maintaining cell agitation at 200 rpm and 37 °C.
[62] The resulting cells were lysed using ultrasonication at ~ 15 W while the lysate was
separated from the debris using centrifugation at 16,000 rpm. Purification of wildtype and
mutants of hFGF1 was carried out using heparin sepharose resin and elution was by a stepwise
NaCl salt gradient buffer containing 10 mM phosphate buffer and 25 mM ammonium sulfate.
[54] Purity and size of the protein of the proteins was confirmed using sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). Molecular weights were compared to prestained standard protein ladder. The protein concentration obtained was measured using UV/Vis
spectroscopy and was in the range of 0.5 mM to 1 mM per liter of bacterial culture.

Fluorescent dye labeling of wildtype and mutant hFGF1
The protocol for fluorescent dye labeling was followed as provided by the vendors of the
dyes with a few modifications. Protein labeling of WT-hFGF1, F2C-hFGF1 and T79C-hFGF1
was carried out with the following series of fluorescent maleimide probes; Alexa Fluor (AF):
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AF488, AF546, AF594 & AF647, Cyanine (Cy®): CY3, Sulfo-CY3 & CY3B and iFluor (iF):
iF647. To increase the efficiency of labeling by all the probes, a protein to dye concentration
ratio of 1:10 in a reaction volume of 30 µL. Reaction conditions employed for labeling with
Alexa Fluor dyes were by using a 10 mM phosphate buffer (pH 7.2) containing 30 % glycerol
and incubating for 2 hrs at room temperature. For cyanine and iFluor dyes, 10 mM phosphate
buffered saline (pH 7.2) also containing glycerol (20 %) was used. Incubation was at room
temperature for 2 hrs followed by overnight at 4 °C. Excess dye was removed by size exclusion
chromatography using a bio-gel P-6DG desalting gel filtration column. Elution was by using the
reaction buffer which did not contain glycerol. Labeling efficiency was determined by recording
UV/Vis spectra with Hitachi U-3900H spectrophotometer to determine the ratio between moles
of dye per moles of protein.

Absorbance and Fluorescence Spectroscopy
Absorbance spectra were recorded on a Hitachi U-3900H spectrophotometer which uses
quartz cuvettes of 1 cm path length. Prior to fluorescent labeling of proteins, concentrations of
protein and dye stocks were measured by recording their respective absorbance. After labeling,
labeling efficiency was determined by recording UV/Vis spectra ranging from 200 nm to 800 nm
to obtain the ratio of dye: protein. All samples were diluted to be within the linear range of
concentration vs absorbance.
Fluorescence spectra were recorded using PerkinElmer LS 55 luminescence
spectrometer. Proteins were excited at 280 nm while emission was collected 10 nm after
excitation between 290 to 400 nm. Concentrations used were diluted to be within the linear
response of the spectrometer.
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Cell proliferation assays
Cell proliferation assays of unlabeled WT-hFGF1 and fluorescently-labeled hFGF1
mutants were carried out as described previously. [63] NIH-3T3 embryonic fibroblast mouse
cells were cultured in DMEM containing 10 % newborn calf serum and 1 %
penicillin/streptomycin in conditions of 5 % CO2 and 37 °C. A media containing ~ 4000 cells/80
ml was aliquoted in 96 well plates and allowed to attach on the surface for 24 hrs. WT-hFGF1
and fluorescently labeled F2C-hFGF1 and T79C-hFGF1 mutants were added at concentrations of
0, 0.4, 2, 10 & 50 ng/mL. The samples were then allowed to incubate for another 24 hrs. Cell
number was determined by CellTiter-Glo luminescent cell viability assay using Synergy2
microplate reader to read signal from viable cells. Calibration curves were also used to calculate
actual cell number in the samples.

Results
Expression, purification and characterization of wildtype, F2C and T79C hFGF1
Expression of WT-hFGF1, F2C-hFGF1 and T79C-hFGF1 was carried out in E.coli
bacterial cells of BL21(DES). Heparin affinity chromatography was used to purify the proteins
which eluted in 1.5 M NaCl buffer. SDS-PAGE (Fig. 2) showed high protein purity of WThFGF1 (lane 2), F2C-hFGF1 (lane 3), T79C-hFGF1 (lane 4) as depicted by single bands (~ 16
kDa) on each lane. Protein concentrations ranged from 0.5 to 1 mM. Since the mutants eluted
from the heparin column at the same salt concentration as WT-hFGF1, this indicated that the
structure of the heparin binding site was not affected by the cysteine mutations, as expected
based on the distant locations of these residues to the heparin binding site (Fig. 1).
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Figure 2. SDS-PAGE analysis of hFGF1 after expression in E.coli and purification with heparin
sepharose affinity chromatography. Lane 1 shows prestained standard molecular weight marker,
lane 2 represents WT-hFGF1, lane 3 shows F2C-hFGF1 and lane 4 indicates T79C-hFGF1.

Further characterization of the protein folding was carried out by using UV absorption
and fluorescence spectroscopy (Fig. 3). Both WT-hFGF1 and mutants showed the same
absorption and emission peak maxima at ~ 278 nm and ~ 309 nm respectively. The excellent
overlap of the absorption spectra with no sloping baseline indicates that there is no aggregation,
which often results from unfolding of proteins that can occur upon site-directed mutagenesis.
Fluorescence spectral peak maxima of aromatic residues are often used to determine the globular
structure of proteins, since these residues show larger Stokes’ shifts when exposed to water upon
disruption of the tertiary structure. [54] Although there is a slight broadening of the emission
peaks of the mutants at longer wavelengths, this effect is small and does not indicate that the
environment of these aromatic amino acids is significantly perturbed.
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Figure 3. Protein folding of WT-hFGF1, F2C-hFGF1 and T79C-hFGF1 after purification. A)
UV spectra of the wildtype (WT-hFGF1) and mutants (F2C-hFGF1 and T79C-hFGF1) showing
maximum absorbance at 278 nm. B) Fluorescence spectra of the proteins exhibiting maximum
emission at 309 nm. Excitation was at 280 nm in 10 mM PBS buffer.

Labeling efficiency of fluorescent probes to wildtype, F2C and T79C hFGF1
WT-hFGF1, F2C-hFGF1 and T79C-hFGF1 were fluorescently labeled with
commercially available maleimide-functionalized probes, the structures of which are shown in
the supplementary information (Figure S1). Fig. 4 shows the UV-Visible absorbance spectra for
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each dye-labeled protein for the F2C and T79C mutants, highlighting the ability to produce
fluorescently labeled hFGF1 across the visible spectral range.
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Figure 4. Efficiency of hFGF1 labeling by fluorescent probes. UV/Vis spectra of fluorescently
labeled hFGF1. Alexa Fluor (AF488, AF546, AF594 & AF647), cyanine (CY3, SulfoCY3,
CY3B & CY5) and iFluor (iF647) maleimide dyes were used for labeling. A) WT-hFGF1, B)
F2C-hFGF1 and C) T79C-hFGF1. Parenthesis indicate the labeling efficiency calculated as ratio
of moles of dye to moles of protein. T79C-hFGF1 aggregated during labeling with AF488,
AF546 & AF594. However, small fractions recovered had absorbance of less than 0.05 which
were below the detection limit of the spectrometer and therefore labeling efficiency could not be
calculated accurately. Spectra of CY5 labeled with WT-hFGF1 is not shown because the protein
aggregated, and no protein fraction could not be recovered.
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These absorbance spectra were used to determine the labeling efficiencies for each dye to
the added cysteine residue at position 2 and/or 79 (Fig. 5 and Table S1). Labeling of WT-hFGF1
is indicative that either one of the native (buried) [57, 64] cysteines are labeled, or that the
protein is non-specifically labeled either by hydrophobic interactions or by reaction of the
maleimide group with an amine group (lysine). WT-hFGF1 exhibited low labeling efficiency (<
15 %) with all the dyes except CY3B, which was slightly higher at 23 %. CY5 is not shown
because the wildtype hFGF1 aggregated during the reaction with this dye. F2C-hFGF1 showed
high labeling efficiencies (>50 %) when labeled with the rhodamine-based, disulfonated Alexa
Fluor dyes of AF488, AF546 & AF594 and the cyanine-based, tetrasulfonated AF647. The fact
that these dyes increased labeling significantly compared to wildtype (Fig. 5A), clearly indicated
site specific labeling to the mutated cysteine. Conversely, F2C-hFGF1 labeled with cyaninebased dyes with either no sulfonation (CY3 & CY5) or disulfonation (SulfoCY3). The structure
of iFluor 647 is proprietary and the company refused to provide information about it, but the
similarity in labeling efficiency to the cyanine-based dyes with either no sulfonation or
disulfonation suggest that it may be cyanine-based. CY3B is a more rigid version of CY3 that
hinders rotation around the polymethine bonds by forming closed ring structures, as well as
being monosulfonated. This structural change increased the non-specific labeling to WT-hFGF1
but only marginally increased the specific labeling to F2C-hFGF1. For fluorescent labeling to the
β turn between sheets 7 and 8 region (T79C-hFGF1), only the cyanine-based dyes labeled with
high efficiencies (Fig. 5B). Interestingly, the rhodamine-based Alexa Fluor dyes (AF488, AF546
and AF594) aggregated the protein during the reaction. The aggregated samples were still put
through the size exclusion chromatography column and a small fraction of labeled protein was
recovered. However, the recovered amount was too small for detection of the labeling efficiency
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by absorption spectroscopy. We would like to highlight here that we attempted to reduce the
tendency for the AlexaFluor based dyes to cause aggregation of the T79C-hFGF1 mutant by
varying the reaction time/temperature, buffer ionic strength and by adding glycerol, but none of
these changes had an effect. Clearly the aggregation is a result of dye-protein interactions once
the dye is attached to the protein and not by the buffer/solvent.
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Figure 5. Bar graph of labeling efficiency of fluorescent probes conjugated to hFGF1.
Maleimide fluorescent probes used were Alexa Fluor (AF488, AF546, AF594 & AF647),
cyanine (CY3, SulfoCY3, CY3B & CY5) and iFluor (iF647). A) Site-specific labeling of F2ChFGF1 relative to non-specific labeling of WT-hFGF1 is shown. B) Site-specific labeling of
T79C-hFGF1 is depicted in comparison to WT-hFGF1 non-specific labeling. Error bars
correspond to 95 % confidence intervals of the mean. Bar graphs of CY5 labeled WT-hFGF1 and
T79C-hFGF1 labeling with AF488, AF546 & AF594 are not shown due to aggregation during
bioconjugation.
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Bioactivity of fluorescently-labeled hFGF1 mutants
While a high labeling efficiency is ideal for fluorescence studies of biomolecules, it is
known that fluorescent labeling can sometimes affect their biological activity. [65, 66] Although
we designed our mutants so that the dye would be located away from the binding site for both
heparin and the membrane-bound receptor, it is still important to determine that our proteins are
still biologically active after labeling. Since hFGF1 is a growth factor, the most common method
to determine biological activity in vivo is to perform cell proliferation assays. [67] The
bioactivity of fluorescent F2C-hFGF1 (Fig. 6A and Table S2) and T79C-hFGF1 (Fig. 6B and
Table S2) was compared to unlabeled WT-hFGF1 as a control. Concentrations of protein were
varied from 50, 10, 2, 0.4 and 0 ng/ml to ensure that we are not under saturating cell proliferation
conditions. The fact that the cell proliferation decreased with decreasing protein concentration,
and that the background levels of cell proliferation are all equal, highlights that we are covering
the correct dynamic range of protein concentration, and thus comparing the relative cell
proliferation at a given concentration (say 50ng/ml) allows us to quantify the relative inhibition
of function resulting from the dye labeling at each position. In general, activities were
maintained upon labeling each position with each dye, although the F2C-hFGF1 mutant labeled
with the rhodamine-based Alexa Fluor (AF488, AF596 and AF546) dyes did show a slightly
lower activity at the highest concentrations of 50ng/ml. It is plausible that the more rigid
rhodamine-based dyes caused a certain degree of steric hindrance towards dimerization of the
FGF/FGFR complex [68], which is known to be important for the phosphorylation of the
intracellular tyrosine kinase region. [14] However, the small reduction in bioactivity combined
with the high labeling efficiency of these dyes in the N-terminal region of hFGF1 suggests that
these dyes are useful fluorescent probes for future studies of FGF/FGFR interactions. Overall,
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labeling either position of the protein with these dyes showed that the presence of the small
covalently attached dyes [69, 70] probes did not significantly affect the activity of hFGF1,
especially at lower concentrations (≤ 10ng/ml).
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Figure 6. Cell proliferation studies of NIH 3T3 cells treated with WT-hFGF1 and fluorescently
labeled F2C-hFGF1 (A) and T79C-hFGF1 (B). Standard errors were determined from triplicate
experiments.

Discussion
A key result from these studies is that the T79C hFGF1 mutant behaved essentially
opposite to the F2C-hFGF1 mutant when exposed to the same dyes under the same conditions.
The cyanine-based dyes labeled with 50-70% efficiency in the more structured β turn but with
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<15% efficiency in the flexible N-terminal region, while the rhodamine-based dyes labeled the
flexible N-terminal region with 80-85% labeling efficiency but caused the protein to aggregate
when attaching to the β turn region. Sulfonation of CY3 to SulfoCY3 caused an increase in
labeling efficiency to the T79C mutant but sulfonation of CY5 to AF647 did not, while the
opposite was true for the F2C mutant; CY3 to SulfoCY3 had a minimal effect, while CY5 to
AF647 had a profound effect.
CY3, SulfoCY3 and CY5 are highly flexible due to rotation of their polymethine groups.
[71] It appears that flexibility of the dye is important when labeling a more structured region,
such as the β turn, but becomes a hindrance when labeling a highly flexible region such as the Nterminal region. One explanation is that there is a balance between the ability of the dye to adopt
to a conformation to allow labeling to a more rigid/structured region while not paying too much
of an entropic penalty for labeling a flexible region. A more rigid dye, such as rhodamine-based
dyes, can label the flexible N-terminal region without paying too much of an entropic penalty.
However, these rhodamine-based dyes appear to interact with the protein when attached to the β
turn region and cause it to aggregate, perhaps by causing it to partially unfold. The ability for the
tetrasulfonated AF647 to efficiently bind to the β turn efficiently without causing the protein to
unfold could be the result of the 4 sulfonate groups being strongly solvated by water to keep the
dye oriented away from the protein and thereby reducing its interaction that would otherwise
cause the protein to unfold/aggregate. A similar explanation of high solvation might also be used
to rationalize why AF647, a cyanine-based dye, can efficiently label the flexible N-terminal
region. The high solvation might reduce the entropic penalty that the less sulfonated flexible
cyanine-based dyes pay when attaching to this highly flexible region of the protein. If our
rationales are correct, it appears that the degree of flexibility of the protein region to be labeled,
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the flexibility of the dyes and the degree of sulfonation/solvation that the dyes experience when
on the protein all play key roles in determining the labeling efficiency. Thus, these results could
be used to more generally and reliably predict which dyes should be able to efficiently label
which regions of proteins. It is still important to test for bioactivity of the protein after labeling,
but if the labeling positions are carefully designed to be away from the binding/active site, and
the fluorescent probes are small enough, the bioactivity of hFGF1 is able to be maintained.

Conclusion
In conclusion, we report fluorescence labeling of hFGF1 with a range of dyes covering
the visible region, which also maintains most of the protein’s biological activity. However, the
efficiency of labeling depends on both the choice of labeling site and on the structural flexibility
of the dye. A certain amount of flexibility in either the dye or the labeling site of the protein is
necessary but having too much flexibility in both dye and protein appears to decrease the
labeling efficiency, perhaps due to the large entropic penalty paid for the conjugation of a
flexible dye to a flexible region of the protein. Furthermore, some dyes caused aggregation of the
protein if they are not able to be solvated (through sulfonation) or be flexible enough to avoid
interaction with the protein. Due to the overall similarity in protein structure across the FGF
family, we anticipate that our results can also be applied to the other 21 FGFs, and even other
proteins that contain both flexible and rigid regions. The labeling of hFGF with a range of
fluorescent dyes at different positions of the protein opens up the potential for them to be used in
structure and dynamics studies of FGF/FGFR/heparin interactions using fluorescence, such as
the ability of measure FRET both at the ensemble and at the single molecule level.
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Figure S1. Structures of maleimide fluorescent probes used for labeling F2C-FGF1 and T79CFGF1 mutants. The structures were drawn using chemdraw as provided by the vendor.
Abbreviations: AF (Alexa Fluor®), CY® (Cyanine). iFluor 647 (iF647, λa = 656 nm, λe = 670
nm) structure is not known due to propriety.
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Table S1: Labeling efficiencies of maleimide fluorescent probes conjugated to F2C-hFGF1 &
T79C-hFGF1 mutants.
Non-specific labeling
efficiency of WThFGF1 (%) a
Site-specific labeling
efficiency of F2ChFGF1 (% ) a
Site-specific labeling
efficiency of T79ChFGF1 (%) a

AF488

AF546

AF594

AF647

CY3

CY3B

CY5

iF647

3

Sulfo
CY3
6

10

14

8

6

23

-

11

85

81

84

63

14

18

41

10

17

-

-

-

50

47

68

55

50

68

a) Labeling efficiency was determined as the ratio of moles of dye to moles of hFGF1.
(-) Indicates samples which aggregated during bioconjugation, and labeling efficiency could not
be determined

61

Table S2: Standard deviation among triplicate cell proliferation assays for WT-hFGF1 and
fluorescent labeled mutants of F2C-hFGF1 and T79C-hFGF1.
F2C-hFGF1
Protein
(ng/ml)

T79C-hFGF1

0

0.4

2

10

50

0

0.4

2

10

50

WT-hFGF1

± 585

± 3310

± 296

± 7416

±1814

± 1160

± 2556

± 2762

± 6417

± 7540

Unlabeled
mutant

±2357

± 1041

± 3714

± 5500

± 2976

± 1497

± 1730

± 2357

± 1667

± 4033

AF488

± 385

± 1891

± 847

± 4223

± 2584

-

-

-

-

-

AF546

± 1161

± 1206

± 2743

± 4805

± 3172

-

-

-

-

-

AF594

± 555

± 2128

± 3829

± 5547

± 4625

-

-

-

-

-

AF647

± 356

± 988

± 5746

± 3031

± 6407

± 585

± 3310

± 296

± 7416

± 5159

CY3

± 1100

± 895

± 1666

± 202

± 4302

± 414

± 529

± 1318

± 6438

± 3325

SulfoCY3

± 511

± 2131

± 1170

± 4196

± 4174

± 564

± 1592

± 892

± 4583

± 9106

CY3B

± 509

± 1431

± 837

± 537

± 2331

± 515

± 3041

± 3270

± 573

± 4765

CY5

± 441

± 3293

± 4118

± 2962

± 4962

± 441

± 3293

± 4118

± 2962

± 4962

iF647

± 914

± 494

± 4943

± 5323

± 1267

± 475

± 1809

± 1000

± 2960

± 2196

(-) Indicates samples which aggregated during bioconjugation, and labeling efficiency could not
be determined for subsequent cell proliferation bioactivity studies.
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Accession Codes

1.

PDB 3JOM

•
•

Heparin-binding growth factor 1 (UniProtKB - P05230 )
Fibroblast growth factor receptor 2 (UniProtKB - P21802)

2.

PDB 1E0O

•
•
•

Fibroblast growth factor 1 (UniProtKB - P05230)
Fibroblast growth factor receptor 2 (UniProtKB - P21802)
Heparin (GlyTouCan: G04280SJ)
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III. Insights into How Labeling Position and Dye Structure Affects the Ensemble and
Single Molecule Properties of Fluorescently Labeled Human Acidic Fibroblast Growth
Factor
Abstract
Signaling of fibroblast growth factor receptor (FGFR) occurs by the binding of human fibroblast
growth factor 1 (hFGF1), with heparin acting as an accessory molecule to help strengthen the
binding association. Binding of hFGF1 to FGFR regulates a plethora of physiological processes
such as angiogenesis, cell proliferation and wound healing. However, when homeostasis is not
maintained by the fibroblast cells, this leads to various cancers. We report the ensemble and
single molecule photophysics properties of site specifically fluorescently labeled hFGF1 mutants
of F2C-hFGF1 and T79C-hFGF1. The F2C position is located on the flexible N terminal loop
while T79C is on the rigid loop between β strands 7 and 8. Maleimide rigid structured
rhodamine-based dyes and flexible structured cyanine-based dyes were used for conjugation of
the dyes to the cysteine residues. Photophysical parameters of ensemble quantum yield,
fluorescence lifetimes and molecular brightness (Ꜫ) were investigated and compared between
free dyes and labeled mutants. Overall results indicated that the parameters depended on the dye
structure, dye local environment, degree of flexibility of the dye and the flexibility of the
labeling site on the protein. Ensemble studies did not always correlate with single molecule
studies as a seemingly quenched dye at the ensemble level was highly fluorescent at the single
molecule level and vice versa. Trolox did not significantly enhance the fluorescen of the probes
as free dyes and when conjugated to the protein. We successfully characterized photophysical
properties of fluorescently labeled hFGF1. This information is critical for designing quantitative
fluorescence studies such as smFRET and in-vivo imaging.

72

Introduction
Human acidic fibroblast growth factor (aFGF), also called human fibroblast growth
factor-1 (hFGF1), is a signaling protein that regulates critical physiological processes such as
wound healing, angiogenesis and embryonic development. [1, 2] It also functions as a mitogen
ligand that stimulates the growth of fibroblast cells connective tissues, upon binding to its
receptor (hFGFR). [3] Further, hFGF1 regulates cellular responses during proliferation,
migration, apoptosis and differentiation. [4-6] An accessory molecule of heparin or heparin
sulfate (HS) is also required to strengthen the affinity of hFGF1 to hFGFR . [7] The family of
FGF is categorized into three subfamilies of hormonal, canonical and intracellular, and hFGF1 is
a universal ligand that can bind all four isoforms of hFGFR. [8] Structurally, wildtype hFGF1
has a β-trefoil topology made up of 12 antiparallel β sheets arranged in three copies of four β
strands. [9, 10] A truncated form of hFGF1 commonly used by researchers, has 141 amino acids
and a molecular weight of ~17 kDa. [9] Due to the direct connection between hFGF1 activity
and cell growth/proliferation, unregulated overexpression of hFGF1 has been associated with a
myriad of human tumors (cancers). For instance, high levels of hFGF1 are used as a biomarker
for the prognosis of pancreatic ductal adenocarcinoma and colorectal cancer. [11-13] Further,
deregulation of hFGF1 induces the epithelial cells to acquire progression of the motile and
invasive mesenchymal-like phenotype which plays an important role in the metastasis of skin
cancer. [14] However, hFGF1 is also very useful in several therapies such as controlling type 2
diabetes mellitus, pulmonary fibrosis and myocardial infarction coronary artery disease. [15, 16]
Due to the connection of hFGF1 with both beneficial and detrimental cell growth, there is a need
to more thoroughly understand the relationship between structure, dynamics and function related

73

to the regulation of hFGF1 in order to better understand the processes underlying the role of
FGF1 in both beneficial therapies as well as cancer pathology.
Single molecule fluorescence has proven to be an excellent technique for studying
structure, dynamics and function of biomolecules, such as the ones related to the binding of
ligands to their receptor. [17] Studying proteins at the single molecule level has a number of
advantages over ensemble-based approaches. Firstly, it reveals heterogeneity hidden in ensemble
averaging which allows for the behavior of exactly one protein molecule to be studied within
complex environments such as fibroblast cells. Secondly, kinetics of various events can be
extracted when under equilibrium conditions by measuring transition rates between states of
single molecules under dynamic equilibrium. Thirdly, it can provide valuable information on
structural transitions undergoing binding events by probing sub-nanometer length-scale changes
using single molecule fluorescence energy transfer (smFRET). [18-20] However, it is critical to
wisely choose both the appropriate fluorescent reporter and the labeling site on the protein in
order to probe the structural behavior of single biomolecules within these complex biological
environments.
Extrinsic fluorophores are heavily used in single molecule fluorescence spectroscopy
because native fluorophores (tryptophan, phenylalanine and tyrosine) of proteins are not bright
or photostable enough to be used as such. [21-24] The three most common types of extrinsic
fluorophores are N- or C-terminal fusions with fluorescent proteins such as GFP or YFP,
inorganic quantum dots such as CdSe/ZnS and organic dyes that can be specifically
functionalized to a specific residue. Each of these fluorophores have specific advantages and
disadvantages that have been previously reviewed in detail. [25] Briefly, the key differences in
each of these types of fluorophores lie in their relative size, brightness, photostability and

74

underlying photophysics. The brightness of a fluorophore is usually defined as the product of
absorption coefficient and ensemble quantum yield, but this definition assumes that all
fluorophores in the ensemble behave identically. This has been clearly shown to be not the case
for inorganic quantum dots, where blinking and the dark fraction play major roles in fluorophore
heterogeneity. [26, 27] However, the role of fluorophore heterogeneity in organic dyes has been
generally assumed to be less of an issue, and ensemble quantum yield is often used as a
determinant for their suitability for single molecule fluorescence studies.
Although other types of dye structure do exist, the two types of organic dye structures
that are most commonly used for single molecule fluorescence studies are rhodamine-based or
cyanine-based, largely due to the commercial availability of high quantum yield functionalized
variants of these probes that are also highly water soluble. [28, 29] Rhodamine-based dyes have
a rigid heterocyclic structure that are photostable and pH insensitive [21, 28], while cyaninebased dyes are more flexible structures consisting of polymethine chains of varying lengths. [30]
This flexibility often results is these dyes exhibiting lower photostability and ensemble quantum
yields compared to rhodamine dyes, although cyanine dyes are particularly known to exhibit an
increase in the ensemble quantum yield upon bioconjugation to proteins. [31] Furthermore, to
increase their water solubility, these dyes are often functionalized with charged sulfonic and/or
carboxylic groups, which may interact with biomolecules when in close proximity, further
complicating predicting how they will act when conjugated to proteins of interest. For smFRET
studies, these dyes are often paired together based on the photophysical properties and ability to
act as donor and acceptor for efficient energy transfer during FRET. For instance, in smFRET
assays rhodamine-based AlexaFluor (AF) 488 (donor) is commonly paired with AF594
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(acceptor) [32] while cyanine-based CY3 (donor) and CY5 (acceptor) are commonly paired in
similar assays. [33]
In order to perform quantitative smFRET assays, it is necessary to attach the dye to the
protein at a specific location. A common bioconjugation strategy is through a thiol-ether bond
formed via a Michael addition between a maleimide moiety on the dye and the sulfhydryl group
of a cysteine amino acid of the protein. [34, 35] This Michael addition is very specific to
cysteines under physiological conditions (pH 7.0-7.5), and the resulting thioether bond is strong
and stable under a wide range of conditions (pH, salt, temperature). Cysteines can either be
endogenous or engineered on the protein by site-directed mutagenesis. The latter is beneficial
when native cysteines are absent or inaccessible for labeling, such as if they are buried within the
core of the protein or exist as disulfide bonds. Site-directed mutagenesis of cysteines has gained
popularity because site-specific labeling can be easily controlled, since native cysteine residues
are rare in proteins. [36, 37] Furthermore, if they are present on the protein surface and are not
involved in disulfide bonds, they can often be mutated away without loss of protein function.
[38] In the case with wildtype hFGF1 (WT-hFGF1), the three native cysteines are buried within
the protein barrel and have been found to not fluorescently label. [39] We have recently found
that both the structure of the dye used and the location of the labeling site on hFGF1 play
significant roles in the labeling efficiency and potential for aggregation during labeling, showing
that both entropy changes upon bioconjugation and dye-protein interactions must be considered
when choosing the combination of dye and labeling region of the protein to optimize labeling
efficiency while maintaining functionality of the protein (manuscript submitted).
In addition to optimizing labeling efficiency, it is necessary to understand how the
fluorescent properties of the dyes are affected once attached to the protein if quantitative
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information is to be drawn from fluorescence assays such as smFRET. As mentioned above, it is
known that some dyes change their ensemble quantum yield when attached to some proteins.
However, it is not obvious if this change in ensemble quantum yield necessarily results in
changes in the brightness at the single molecule level. Molecular brightness describes the
fluorescence counts per molecule per second (cpms) measured at the single molecule level. [25,
28] Organic dyes can have undesirable optical properties that can deteriorate their photophysical
performance which may depend on a wide range of parameters related to the environment that
they experience. For example, some dyes are known to blink, whereby the fluorescence intensity
repeatedly switches between on and off states. This can be detrimental for single molecule
studies like smFRET which relies on continuous emission of fluorescence by reporters. [40-42]
Blinking is mainly caused by triplet state formation and excited-state isomerization or redox
reactions. Photooxidation reactions in the triplet state can also lead to photobleaching which
significantly decreases observation time at the single molecule level. Trolox (an analog of
vitamin E) is commonly used in single molecule fluorescence experiments to help depopulate the
triplet state, decreasing blinking and increasing photostability. [43-45] Trolox by itself acts as a
reductant but can also act as reducing & oxidizing system (ROXS) upon its partial degradation
by oxidation to trolox-quinone. [44] In addition to blinking quenching reactions can also reduce
the fluorescence intensity of fluorophores. [46, 47]
As previously reported, differences in the labeling efficiency of hFGF1 resulted from
both the flexibility of the dye and the labeling site of the protein (manuscript submitted). In this
study, we extend this study to determine the effect of the combination of dye structure and
labeling site on the photophysical properties of the dyes once they attached to the protein. Two
protein labeling sites were chosen: a more flexible region at the N-terminus of the protein (the
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F2C mutant) and a more rigid region on a β turn between sheets 7 and 8 (the T79C mutant).
Similarly, a range of dyes covering the visible spectrum were used including more rigid
rhodamine-based dyes and more flexible cyanine-based dyes. By comparing the ensemble
quantum yield, molecular brightness, number of fluorescent molecules per unit volume and
fluorescence lifetime decay, we find that a combination of dynamic and static quenching can
exist for some combinations of dye and labeling position that can result in a disconnect between
the fluorescence properties at the ensemble level compared to the single molecule level.
However, for other combinations, the ensemble and single-molecule fluorescence properties
correlated well, indicating more simple quenching/dequenching mechanisms at play. We also
find that the presence of Trolox, a commonly used triplet-quenching additive for single molecule
fluorescence studies, influenced some dye-labeling site combinations but not others. We
describe the underlying rationale for these effects in terms of both the dye structure and the
flexibility in the labeling position. Our results should allow for a more systematic understanding
of the factors underlying static and dynamic quenching in proteins in order to optimize the
combination of dye and labeling position to produce highly fluorescent proteins for single
molecule fluorescence studies.

Materials and Methods
Reagents
The site-directed mutagenesis kit Quikchange II XL was from Agilent Technologies
(Santa Clara, CA, USA). DNA plasmid of pET20b was obtained from Qiagen (Germantown,
MD, USA) and primers were purchased from IDT DNA Technologies (Coralville, IA, USA).
DH5α and BL21(DES) competent cells were supplied by Novagen (Madison, WI, USA) while
the Luria Broth (LB) agar and broth were from EMD Millipore (Burlington, MA, USA). Buffer
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salts (NaCl, NH4SO4, Na2HPO4 and NaH2PO4), Ampicillin and Isopropylthio-β-D-galactoside
(IPTG) were purchased from VWR (Radnor, PA, USA). Cyanine 3B (CY3B) and Heparin
Sepharose resin were obtained from GE Healthcare (Chicago, IL, USA) while Biogel-P6 resin
was from Biorad (Hercules, CA, USA). Alexa Fluor dyes (AF488, AF546, AF594 & AF647) and
Tetraspeck Microsphere (0.1 µm) fluorescent beads were purchased from Thermo Fischer
Scientific (Waltham, MA, USA). Cyanine (CY3, SulfoCY3 & CY5) and IFluor (IF647) dyes
were supplied by Lumiprobe Corporation (Hunt Valley, MD, USA) and AAT Bioquest
(Sunnyvale, CA, USA) respectively. Trolox and Glycerol were from Sigma Aldrich (St Louis,
MO, USA).

Cloning, Expression and Purification of FGF1 variants
For our experiments, a truncated form of acidic wildtype protein (WT-hFGF1) of 141
amino acids (~17 kDa) was used to design two mutations at positions F2C-hFGF1 and T79ChFGF1 [48, 49]. Cloning of WT-hFGF1 DNA was carried out in pET20b vector while primers
were designed as described in the QuikChange II XL kit. After PCR, plasmids were transformed
into DH5α cells, grown on agar and isolated using Qiagen kit. The two mutations sequences
were confirmed by a sequencing facility at Molecular Resource Laboratory, University of
Arkansas for Medical Sciences, Little Rock, AR. Plasmids of wildtype and mutants were further
transformed into BL-21(DE3) E.coli cultured cells and overexpressed in LB media (10 %
ampicillin & IPTG) with cell agitation maintained at 200 rpm and 37 °C [50]. Harvested cells
were lysed by ultrasonication (~15 W) and ultracentrifuged at 16,000 rpm in order to remove the
lysate from the debris. Lysate was loaded onto a heparin-sepharose column for protein
purification and elution was achieved a stepwise NaCl salt gradient [51]. Size and purity were
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compared to a protein ladder using sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). UV/Vis spectroscopy (Hitachi U-3900H spectrophotometer) was used to
determine the protein concentration and it ranged from 0.5 mM to 1 mM per liter of bacterial
culture.

Fluorescence Labeling of hFGF1
Wildtype hFGF1 (WT-hFGF1) and site-specific cysteine mutants (F2C-hFGF1 & T79ChFGF1) were fluorescently labeled with either the Alexa Fluor® (AF) dyes of AF488, AF546,
AF594 & AF647, the Cyanine (Cy®) dyes of CY3, Sulfo-CY3, CY3B & CY5, or the IFluor (IF)
dye of IF647. For fluorescent labeling, a protocol provided by each respective dye vendor was
followed with minor modifications. A protein to dye concentration ratio of 1:10 in a reaction
volume of 30 µL was maintained. The reaction buffer used for labeling AF dyes was 10 mM
phosphate buffer (PB, pH 7.2) containing 30 % glycerol while, incubation was for 2 hrs at room
temperature. Buffer conditions used for labeling with CY and IF dyes were 10 mM phosphate
buffered saline (PBS, pH 7.2, containing 20 % glycerol, 100mM NaCl and 50 mM AMS) with 2
hrs incubation initially at room temperature, followed by overnight at 4 °C. Size exclusion
chromatography (SEC) with a bio-gel P-6DG desalting gel filtration column was used to
removed excess unreacted dye. For elution of labeled protein, the same reaction buffers were
used without glycerol. Hitachi U-3900H spectrophotometer was used to record UV/Vis spectra
so that the Beer-Lambert law could be used to determine the labeling efficiency defined as the
ratio between moles of dye per moles of protein.

Ensemble Quantum Yield
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Ensemble quantum yield (QY) of site-specifically fluorescently labeled F2C-hFGF1 and
T79C-hFGF1 mutants was measured using a dye standard in the appropriate solvents. [52]
Fluorescence emission of free dyes and labeled protein were compared to those of known
standards from the reference dye sampler kit under identical excitation and concentration
conditions. Fluorescence and absorbance spectra were recorded using PerkinElmer LS 55
luminescence spectrometer and Hitachi U-3900H spectrophotometer respectively. Excitation of
the dyes and their respective references was at the same wavelengths using slit widths of 5 nm
for both excitation and emission. Fluorescence intensity spectra collected for all the samples was
10 nm after the excitation wavelength up to 800 nm. A linear (R2 = 0.999) graph of absorbance
vs integrated fluorescence intensity for the respective samples and standards was plotted and QY
was determined. QY was measured in buffer-only (no Trolox) and in buffer containing 2mM
Trolox.

Single Molecule Fluorescence
Single-molecule fluorescence was measured on a Microtime 200 microscope (Picoquant
GmbH, Berlin, Germany) fitted with PicoHarp 300 (TCSPC) controller. [53, 54] It is equipped
with picosecond diode-pumped solid-state (DPSS) lasers at 485 nm and 640 nm. A diffractionlimited laser focus for excitation of the sample was achieved by directing the laser to a water
immersion objective lens (Olympus IX71, apochromat, 60x, NA = 1.3) via a dichroic mirror
suitable for each laser. The same objective lens was used to collect fluorescence which was then
passed through the same dichroic mirror and a 50 µm pinhole. The objective lens is also placed
on a sub-nanometer 3D piezo scanning stage from PI (Berlin, Germany) to enable images to be
obtained via raster scanning of the stage on which the coverslip sits. A single photon avalanche
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diode detector (MPD, SPAD) from Microphotonic Devices (Bolao, Italy) was used with a filter
(Chroma, Vermont, USA) placed before the detector in order to reject background fluorescence
and light scattering. Dichroic mirror used was FF562-Di03 and FF641-Di03 respectively from
Chroma. Collected photons were passed through 520/35 and 690/70 for the respective blue and
red laser excitation. The data from the detectors provided time-tagged time-resolved (tttr) single
photon traces that allowed for off-line, subsequent data analysis that will be described below.
Fluorescence traces were collected from a 50 uL drop of the sample solution placed on a
#1 glass coverslip. The glass surface was blocked from protein absorption using 1 mg/ml of BSA
added prior to the sample being placed on the coverslip. The focus was placed ~ 30 µm above
the glass surface to ensure that freely diffusing molecules were measured. Since F2C-hFGF1 and
WT-hFGF1 labeled with AF dyes were eluted in PB buffer on the SEC column, saline was added
to the sample in order to improve protein stability. For fluorescently-labeled T79C-hFGF1,
additional saline was not required since it was already eluted in PBS. Prior to adding to the
coverslip, all samples were centrifuged at 14,000 rpm for 5 minutes in order to remove
aggregates. Fluorescence traces for both free dyes and labeled proteins were collected in PBS
buffer in “no trolox” and 2mM “trolox” solution conditions. 485 nm laser excitation was used to
excite the AF488 dye at a power of 10 µW. The 485 nm laser was also used to excite the green
dyes (CY3, SulfoCY3,CY3B & AF546) using a power of 200 µW. The red dyes (AF647, CY5 &
iF647) were excited with the 640 nm laser at a power of 50 µW. These powers were carefully
considered to minimize the effects of afterpulsing and deadtime which can reduce the number
photon counts measured. [55] The acquisition time for collecting the traces was 2 min. To obtain
good signal to noise ratio for fitting FCS and PCH, average photon count rates were maintained
in the order of 104 to 105 counts/s. Dye concentration of free dyes and on labeled proteins were
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adjusted accordingly and remained in the nanomolar (nM) range, with the specific concentrations
reported in the text.

Data Analysis using Fluorescence Correlation Spectroscopy (FCS)
FCS is a technique that correlates the temporal fluctuations of fluorescence intensity of
molecules emitting photons as they pass through a confocal volume. [56, 57] Self-similarity of
the temporal fluctuations is quantified by plotting an autocorrelation function (ACF) as a
function of lag time and is expressed by the following equation;

𝐺(𝜏) =

𝛿𝐹(𝑡)− 𝛿𝐹(𝑡+𝜏)

(1)

<𝐹(𝑡)2 >

where 𝐺(𝜏) is the ACF. [58-60] The δF(t) and δF(t+τ) are fluorescence intensities at time t and at
a subsequent time (t + τ) respectively, and <F(t)> is the average fluorescence intensity over the
whole trace. To obtain quantitative information from ACF, mathematical models are applied to
account for diffusion as well as other processes, such as triplet state formation, that contribute to
the intensity of the fluctuations. [61] For our experiments, FCS curves were plotted and fitted
using the Symphotime 64 software (Picoquant). Pure lateral diffusion occurs in the order of
milliseconds while the faster photophysical process of triplet state occurs on the microsecond
timescale, which can both be observed in the ACF. [59] Therefore, the fitting model used
expressed the ACF as follows

𝐺(𝜏) = [1 − 𝑇 + 𝑇𝑒

(−

𝜏
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𝜏𝑇

𝜏 −1

] ∑𝑛𝑖=1 𝜌𝑖 (1 + 𝜏 )
𝑖

𝜏

−1/2

(1 + 𝜏 к2 )
𝑖

(2)
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where T is the average fraction of molecules in the triplet state, τT is the lifetime of the triplet
state, τi is the diffusion time of molecules passing the effective volume. In our data, we found
that a single diffusing species was enough to fit the data (n = 1), highlighting that the protein was
not aggregated, and that free dye was efficiently removed. к2 is the parameter describing the size
and shape of the effective volume (Veff), as described below.

𝑍

к2 = 𝑊0

(3)

𝑉𝑒𝑓𝑓 = 𝜋 3/2 𝑤𝑜2 𝑧𝑜

(4)

0

whereby, wo and zo are the respective radii of lateral and axial beam waist (1/e) of the threedimensional gaussian (3DG) point spread function (PSF). The radii have to be measured
experimentally using known standards. For our experiment, sub-resolution fluorescent scanning
beads (100 nm) were used and imaged using the piezo scanner on the Microtime 200 system.
Calculations using respective Eqn. 3 and 4 yielded Veff of 0.8 ± 0.1 fL and к2 of 3.
Once these two important parameters were measured, this allowed the diffusion coefficients (Di)
to be calculated from the lateral diffusion time (τi)

𝑤2

𝐷𝑖 = 4𝜏𝑜

(5)

𝑖

In addition, fitting also provides the amplitude of the ACF extracted to time 0 (Go) from which
the average number (N) of fluorescent molecules in Veff is determined and, subsequently, the
average molecular brightness (ꜪFCS)

𝛾

𝑁𝐹𝐶𝑆 = 𝐺

(0)

(6)
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𝐼

Ꜫ𝐹𝐶𝑆 = 𝑁

(7)

where, NFCS is the average number of molecules in the focal volume (Vfocal, not Veff), 𝛾 is the
gamma factor describing the PSF focal shape contours independent of Vfocal and G(o) is the
amplitude of the ACF curve. [62] After NFCS was determined, ꜪFCS was calculated by dividing
the average intensity (I, photon counts per seconds) of the traces by NFCS, thus yielding ꜪFCS with
units of counts per molecule per second (cpms). The factor G(o) from the ACF is inversely
proportional to NFCS because FCS is based on the poisson distribution (P(x; μ) = (e-μ) (μx) / x!)
that describes the probability of x fluorophores being present when the average number of
molecules in the 1 fL confocal volume is μ. [47] Typically, a 1 nM concentration has μ = 0.6
molecules and therefore, one can say the probability of finding zero fluorophores in the confocal
volume is 55 %. [47] However, when x is 1, the probability becomes 33 % and it is for this
reason that the amplitude of FCS (G(o)) is inversely proportional to NFCS or concentration. In
order for Eqn.6 and 7 to be used to extract ꜪFCS, 𝛾 must be determined experimentally.
Tetraspeck multifluorescent beads were used to measure the 3DG PSF (xyz) intensities (I), which
were then fitted into 𝛾 equation described as follows [63, 64]

𝛾=

∫ 𝐼 2 (𝑥,𝑦,𝑧)𝑑𝑥𝑑𝑦𝑑𝑧
∫ 𝐼 (𝑥,𝑦,𝑧)𝑑𝑥𝑑𝑦𝑑𝑧

(8)

Using Eqn.8, the gamma factor (𝛾) obtained was 0.2611 for the 485 nm laser and 0.2474 and for
640 nm laser.

Data analysis using the photon counting histogram (PCH)
The same fluorescence traces collected for plotting the FCS curves were also used to plot
PCH curves, in order to determine the average ꜪPCH to provide a second fitting method of finding
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the molecular brightness. Construction of histograms was performed using the FFS Data
Processor 2.7 software purchased from Scientific Software Technologies Center (SSTC, Minsk,
Belarus). Data was binned at 50 µs while fitting of the PCH model to experimental curves
extracted ꜪPCH in counts per molecule per bin time or cpms. Unlike FCS, the software extracted
NPCH as the average number of molecules in Veff instead of Vfocal, which is much larger that the
Vfocal by a factor of 23/2. [65] As a result, NPCH was multiplied by the gamma factor (𝛾) in order
to obtained N values similar to those from FCS. PCH data fitting was well established by Chen
and co-workers for a two-photon excitation which uses Gaussian-Lorentz PSF, as well as for a
confocal setup which employs the 3DG PSF profiles. [66] However, it has been shown that for a
one photon excitation confocal setup, such as the one used by our microscope, the data suffered
from out-of-focus emission leading to a deviation from a theoretical 3DG profile, which led to
less than perfect fitting of the data using the two-photon PSF. [67, 68] Therefore, this software
applies a semi empirical model to correct for out-of-focus emission via a correction parameter
(Fc1) [67, 68], which improves the reduced chi-squared (𝜒 2 ) parameter that describes the
goodness of the fits. The PCH model established by Chen and co-workers [66] was improved by
the Zare group to incorporate the Fc1 parameter and its described as follows [67],

∞

1
П(k; NPSF , Ꜫ) =
∑ 𝑝𝑁 (k; V0 , Ꜫ) 𝑝# (𝑁)
(1 + 𝐹𝑐1)2

(𝑘 > 1)

(9)

𝑁=0

where the function of П(k; NPSF , Ꜫ) describes the probability of observing k photons in the
volume for a solution with a known concentration.
Fluorescence Lifetime Decay
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Measurements of fluorescence lifetimes were also carried out on the Microtime 200
system. However, a pulsed laser instead of a continuous laser was used with a repetitions rate of
2.5 MHz to excite the samples. Data was averaged for a total of 60s, with emitted photons
histogrammed into 4096 time-resolved channels with a resolution of 4ps per channel, following
the excitation pulse. This was performed using the time correlated single photon counting
(TCSPC) electronics that measures the time delay between the excitation pulse and the emitted
photon from the fluorophore. The histograms were exported as ASCII files and fitted on the
freely-available program DecayFit (Analysis Software 1.3, FluorTools, www.fluortools.com)
which uses the instrument response function (IRF) for iterative reconvolution fitting.

Results
Ensemble Quantum Yield
Fig.1 shows QYs (expressed as percentages) for both mutants labeled with a range of
fluorescent dyes, as well as the corresponding free dyes in the same buffer. The F2C mutant
labeled the flexible N-terminus, while the T79C mutant labeled the more rigid β-turn region
between sheets 7 and 8. Two buffer conditions were used, differing only in whether Trolox was
added or not. Our earlier study reported that the more rigid Rhodamine-based dyes could not
label to the more rigid region in the T79C mutant without causing protein aggregation due to
steric effects resulting in dye-protein interactions (manuscript submitted), and so no QY data is
reported for those combinations. Overall, significant differences in QY were usually observed
between the free dye and the dye once attached to the protein. In general, the Rhodamine-based
dyes of AF488 and AF546 showed significant decreases in QY upon attachment to the protein,
while the cyanine-based dyes of Cy3, SulfoCy3 and Cy5 showed increases in QY upon
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attachment to the protein. However, this was not always the case. For example, the cyaninebased dye of AF647 showed a decrease in QY in both mutants, although it showed a larger
decrease in the more flexible F2C region. The rigid cyanine-based dye, Cy3B, was mostly
unaffected in QY by conjugation to both regions of the protein. The proprietary dye, ifluor647,
showed similar to behavior to Cy5 in both protein regions, indicating that these 2 dyes are
probably very similar in structure.
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Figure 1. Quantum yield (QY) comparison between free fluorescent dyes to labeled hFGF1
mutants. QY was determined in “no trolox” and in “trolox”. Panel a) QY of labeled F2C-hFGF1
compared to free dyes. Panel b) QY of labeled T79C-hFGF1 relative to literature to free
fluorescent dyes. Error bars correspond to 95 % confidence intervals of the mean. Standards of
known QY from reference dye sampler kit were used. Bar graphs of T79C-hFGF1 labeled with
AF488, AF546 & AF594 are not shown as it aggregated during bioconjugation. Standards of
known QY from reference dye sampler kit were used. Labeled WT-hFGF1 was not measured
because unlike the mutants, it exhibited low labeling efficiency due to non-specific labeling, as
the three native cysteine are buried with the barrel shape and are not easily accessible to the
maleimide moiety of the dyes. QYs values compared to other photophysical parameters are
shown in Fig 4, table I and II.
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Trolox is a known triplet state quencher with redox properties, and is often added to the
buffer for single molecule measurements to improve photostability. Since it is a triplet state
quencher, one might expect that Trolox would improve the QY of the fluorescent label.
However, we observed that, in most cases, Trolox either did not affect the QY of the dye when
on the protein or it sometimes decreased it. For example, both Cy3B and IF647 showed a
significant decrease in QY in both F2C and T79C, with the effect being much more pronounced
in T79C for both dyes. Interestingly the QY of the flexible cyanine-based dye, Cy5, was
quenched by Trolox in the T79C mutant, but was not affected in the F2C mutant (in fact it
increased very slightly). A slight increase in (the already very low) QY of the rhodamine-based
AF546 by Trolox was also observed for the F2C mutant, although the structurally similar AF488
showed a decrease in (the already very low) QY.

Molecular Brightness Analysis from FCS and PCH
FCS and PCH analyses were used to extract the average molecular brightness (Ꜫ) and the
number of molecules in the observation volume (N) for free fluorescent dyes vs their respective
fluorescently labeled wildtype (WT-hFGF1) and labeled mutants (F2C-hFGF1 and T79ChFGF1) proteins. Fig. 2 shows FCS and PCH curves of CY3 and its labeled proteins as an
example of curves used to determine the photophysical parameters summarized in table I (no
trolox) and II (trolox). Supplementary Fig.S1 shows all the FCS and PCH curves for all the dyes
and their respective labeled proteins. Residuals from both FCS and PCH are also shown
underneath the curves. In both Fig.2 and Fig.S1, the left side panels are measurements taken
without trolox and the right side panels are taken with trolox in the buffer. These FCS and PCH
curves for each respective dye and its labeled proteins, were fitted using the same fluorescence
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traces and the goodness of the experimental fits were both expressed by reduced chi squared
(𝜒 2 ) shown in the tables. In addition, the first order correction factor (Fc1) for the PCH curves is
also shown in the tables as it corrects for the out of focus emission from the one photon confocal
excitation [67, 68] used in our experiments. Concentrations, as measured by dilution from the
stock solutions used to collect the fluorescence traces are also stated in tables I and II. Molecular
brightnesses extracted from PCH and FCS in in general agreement. However, when the Fc1
correction factor from PCH was >1, there was an overestimation of ꜪPCH by ≥30 % when
compared to ꜪPCH from FCS. Therefore, the influence of these statistical fitting parameters on the
extracted ꜪPCH and ꜪFCS were considered when reporting the results.
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Figure 2. FCS and PCH used to extract the average molecular brightness (Ꜫ) and the number of
fluorescent molecules (N) of free CY3 dye vs labeled WT-hFGF1-CY3, F2C-hFGF1-CY3 and
T79C-hFGF1-CY3 recorded in “no Trolox” (left side panels) and “trolox” (right side panels).
Both ACF and PCH (bin time 50 µs) are plotted from the same fluorescence intensity traces
sampled for 2 min. Panels a1 is ACF and Panels b1 is PCH. Molecular brightness (Ꜫ) measured
in cpms using the ACF was calculated by dividing the average photon count intensity (counts/s)
from the traces by the number (N) of fluorescent molecules as determined using Eq.7 & 8. A fit
of ACF using the triplet state model leads to random residual distribution as shown below the
ACF curves. Fitting of the one photon excitation PCH applied first order correction parameter
(Fc1) and reduced chi-squared (𝜒 2 ) analysis was applied to both ACF and PCH. Supplementary
section (S1) shows the rest of the ACFs and PCHs curves for all the dyes and their labeled
proteins. All photophysical parameters obtained from both curves are summarized in table I & II
and compared on the bar graph shown in Fig 4.
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Table I: Summary of photophysical parameters of free dyes compared to their respective
fluorescently labeled mutants of F2C-hFGF1 and T79C-hFGF1 measured in “no trolox” buffer
conditions.
FCS

AF488
WT-hFGF1-AF488
F2C-hFGF1AF488
CY3
WT-hFGF1-CY3
F2C-hFGF1-CY3
T79C-hFGF1-CY3
SulfoCY3
WT-hFGF1SulfoCY3
F2C-hFGF1SulfoCY3
T79C-hFGF1SulfoCY3
CY3B
WT-hFGF1-CY3B
F2C-hFGF1-CY3B
T79C-hFGF1CY3B
AF546
WT-hFGF1-AF546
F2C-hFGF1AF546
AF594
WT-hFGF1-AF594
F2C-hFGF1AF594
AF647
WT-hFGF1-AF647
F2C-hFGF1AF647
T79C-hFGF1AF647
IF647
WT-hFGF1-IF647
F2C-hFGF1-IF647
T79C-hFGF1IF647
CY5
F2C-hFGF1-CY5
T79C-hFGF1-CY5

PCH

LE
(%)
10

QY
(%)
75.97
-

Lifetime
(ns)
4.11
-

Conc.
(nM)
50
150

NFCS
8.42
11.02

ꜪFCS
26951
21149

χ2
1.083
2.760

NPCH
9.10
11.77

ꜪPCH
24090
21310

Fc1
0.317
0.456

χ2
1.066
1.596

85
3
14
47
-

9.73
2.01
13.32
18.01
4.25

3.10
0.31
1.10
1.23
0.42

450
100
100
100
100
100

3.78
10.36
5.72
5.75
13.32
14.10

17996
3668
12756
12172
11635
8833

1.215
1.083
1.083
1.083
1.208
1.083

4.34
7.58
6.29
4.87
12.19
8.65

21720
5066
22120
30400
22590
10800

0.534
0.347
1.333
1.845
1.403
0.627

0.911
1.090
3.058
6.050
1.751
1.114

6

-

-

100

9.85

32782

1.083

10.36

52170

1.26

1.936

18

27.12

1.27

100

11.45

29864

1.083

10.33

41130

1.207

1.192

68
23
41

31.80
84.97
64.20

1.58
2.56
2.81

100
50
50
50

8.85
4.36
3.56
3.84

34573
73871
79729
88028

1.067
1.083
1.083
1.083

9.38
4.85
3.80
4.07

49900
115000
120600
128900

1.069
1.272
1.181
1.148

1.295
5.579
3.208
5.395

55
14

65.22
30.11
-

2.60
3.89
-

50
50
60

3.80
2.74
2.70

101448
76204
77775

1.083
1.083
1.083

4.08
2.93
2.40

160300
83750
89480

1.29
0.584
0.386

5.395
1.362
1.143

81
8

3.10
42.94
-

3.36
-

400
-

2.03
-

85764
-

1.083
-

2.06
-

98480
-

0.531
-

1.320
-

84
6

2.43
23.98
-

1.68
-

40
50

7.83
6.66

29371
46477

1.083
1.648

7.98
7.08

29670
47980

0.469
0.566

1.532
1.258

68

9.53

1.27

70

4.63

49202

0.820

4.77

57480

0.717

0.955

59
10
18

14.33
8.16
63.03

1.58
0.99
1.65

50
50
50
50

6.13
7.57
5.50
5.39

40979
26429
46372
44703

1.083
1.083
1.083
1.083

6.08
7.32
5.45
5.66

45720
27180
50960
50450

0.578
0.416
0.556
0.691

1.521
1.070
1.136
1.723

68
11
50

85.53
12.85
34.67
56.71

2.15
0.54
1.46
1.58

40
200
70
70

3.49
8.00
5.51
5.55

86528
20604
56974
66687

1.083
1.083
1.090
1.119

3.92
7.71
5.75
5.46

85960
21390
69940
76180

0.591
0.43
0.841
0.611

1.011
1.304
1.499
1.662

-

(-) parameters which were not measured.
(LE) labeling efficiency.
(QY) ensemble quantum yield.
(Conc.) measured concentration for fluctuation traces used to fit FCS and PCH data.
(NFCS) the average number of fluorescent molecules in the focal volume from the FCS.
(ꜪFCS) the average molecular brightness measured from the FCS.
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Table I: (Cont.)
(NPCH ) the average number of fluorescent molecules in the effective volume extracted from
PCH.
(ꜪPCH) the average molecular brightness extracted from the PCH.
(Fc1) first order correction factor for one photon PCH.
(χ2) reduced chi squared analysis

Table II: Summary of photophysical parameters of free dyes compared to their respective
fluorescently labeled mutants of F2C-hFGF1 and T79C-hFGF1 measured in “Trolox” buffer
conditions.
FCS

AF488
WT-hFGF1-AF488
F2C-hFGF1-AF488
CY3
WT-hFGF1-CY3
F2C-hFGF1-CY3
T79C-hFGF1-CY3
SulfoCY3
WT-hFGF1SulfoCY3
F2C-hFGF1SulfoCY3
T79C-hFGF1SulfoCY3
CY3B
WT-hFGF1-CY3B
F2C-hFGF1-CY3B
T79C-hFGF1CY3B
AF546
WT-hFGF1-AF546
F2C-hFGF1-AF546
AF594
WT-hFGF1-AF594
F2C-hFGF1-AF594
AF647
WT-hFGF1-AF647
F2C-hFGF1-AF647
T79C-hFGF1AF647
IF647
WT-hFGF1-IF647
F2C-hFGF1-IF647
T79C-hFGF1IF647
CY5
F2C-hFGF1-CY5
T79C-hFGF1-CY5

PCH

LE
(%)
10
85
3
14
47
-

QY
(%)
65.67
3.10
2.65
14.95
22.00
3.54

Lifetime
(ns)
3.99
2.28
0.40
1.35
1.58
0.42

Conc.
(nM)
50
150
450
100
100
100
100
100

NFCS
10.32
10.04
2.67
19.78
8.21
8.11
14.67
16.42

ꜪFCS
23643
23401
21757
2679
14002
12579
15953
8647

χ2
1.083
1.513
1.083
1.083
1.083
1.456
1.088
1.083

NPCH
10.36
11.60
2.60
11.04
7.72
7.46
9.57
15.45

ꜪPCH
22400
20320
26730
3841
29700
29900
22180
6931

Fc1
0.284
0.357
0.624
0.591
1.686
1.958
1.044
0.577

χ2
1.042
0.942
1.259
1.255
2.947
6.107
1.796
1.960

6

-

-

100

9.39

28322

1.094

13.78

38550

1.045

0.862

18

21.09

1.27

100

11.06

33624

1.403

11.32

43880

1.053

0.762

68
23
41

22.18
76.59
48.44

1.52
2.56
2.81

100
50
50
50

5.03
3.96
2.84
3.05

37370
80636
105944
109172

1.535
1.700
1.083
1.083

4.97
4.34
2.99
3.23

57490
112700
131100
135000

1.051
1.074
0.762
0.768

1.410
2.939
1.538
1.760

55
14
81
8
84
6
68

26.00
22.76
4.17
53.81
2.03
22.43
3.42

2.60
3.81
3.56
1.22
1.72

50
50
60
400
40
50
70

3.431
4.92
2.58
1.64
9.74
5.49
4.49

98512
64071
65438
81755
30178
46372
44533

1.083
1.083
1.083
1.083
1.083
1.652
1.088

3.60
3.76
2.71
1.70
10.35
6.34
4.59

109800
83460
85130
87570
25930
40260
51530

0.581
0.952
0.922
0.510
0.301
0.425
0.691

1.294
1.562
1.651
1.368
1.106
0.96
0.992

59
10
18

15.23
10.32
39.65

1.34
1.00
1.95

50
50
50
50

8.38
11.89
5.78
5.16

41725
26225
45835
51403

1.140
1.142
1.083
1.083

8.99
12.44
6.10
6.55

41040
23020
49010
46970

0.503
0.309
0.610
0.658

0.958
1.334
1.294
1.108

68
11
50

38.38
14.12
39.30
17.24

2.15
0.40
1.35
1.58

40
200
70
70

3.235
9.63
4.97
3.217

82233
20979
49306
69300

1.083
1.083
1.066
1.092

5.78
9.60
4.90
3.22

48510
21780
61130
81550

0.672
0.477
0.747
0.678

1.425
1.077
1.720
1.072
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Table II: (Cont.)
(QY) ensemble quantum yield.
(Conc.) measured concentration for fluctuation traces used to fit FCS and PCH data.
(NFCS) the average number of fluorescent molecules in the focal volume from the FCS.
(ꜪFCS) the average molecular brightness measured from the FCS.
(NPCH ) the average number of fluorescent molecules in the effective volume extracted from
PCH.
(ꜪPCH) the average molecular brightness extracted from the PCH.
(Fc1) first order correction factor for one photon PCH.
(χ2) reduced chi squared analysis

The most important result from the single molecule brightness studies is that even when
the ensemble QY reduces significantly upon conjugation to the protein, it does not necessarily
mean that the molecular brightness also decreases. For example, the QY of free AF488 is 75.97
% while the molecular brightness 26951 cpms as measured by FCS (or 24090 cpms as measured
by PCH). Upon conjugation to the F2C mutant (with an 85% labeling efficiency), the QY
decreases significantly to 9.73 % while the molecular brightness only reduces to 17996 cpms as
measured by FCS (or 21720 cpms as measured by PCH). It is important to note that, in order to
obtain similar average count rates to the detector, it was necessary to increase the concentration
from 50 nM for the free dye to 450 nM for the labeled protein. This result indicates that the
reason that the ensemble QY decreased while the molecular brightness remained very similar is a
result of a significant “dark fraction”. The “dark fraction would contribute to decreasing the
ensemble QY but would not show up in a single molecule fluorescence measurement, while the
“bright fraction” behaves similarly to the free dye at the single molecule level. It is also
important to note that we also measured the molecular brightness of dyes exposed to wt-hFGF1.
These dyes would bind non-specifically to the wt protein and, although the efficiencies of these
non-specific bindings of dye to the protein are low (<15 %, with the sole exception of Cy3B that
showed 23 % non-specific binding), it is important to measure their molecular brightness to
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ensure that these few non-specifically bound dyes are not especially bright that would contribute
to increasing the overall molecular brightness. In all cases, the wt protein showed very similar
molecular brightness as the mutant proteins, highlighting that these few non-specifically labeled
proteins do not skew the results towards higher molecular brightness.
While AF488 is an interesting example highlighting the fact that while QY can change
significantly upon conjugation, the molecular brightness of single molecules may not, other dyes
show changes in both QY and molecular brightness. This is particularly true of the cyanine dyes
that increase in QY when conjugated to the protein. Cy3 increases in QY from 2.01 % to 13.32
% (F2C) or 18.01 % (T79C), which is a 6.6 – 9.0 fold increase. The molecular brightness of Cy3
increases from 3668 cpms to 12172 cpms (F2C) or 11635 (T79C), which is a 3.2 – 3.3 fold
increase, just slightly less than the increase in QY. Other flexible cyanine dyes, SulfoCy3 and
Cy5 have similar trends, as does IF647, which has an unknown structure but is likely similar to
Cy5 based on the results in this manuscript.
The most interesting results from these experiments are when the changes in QY are
opposite to the changes in molecular brightness upon conjugation to the protein. For the rigid
cyanine dye, Cy3B, the QY decreases from 76.59 % to 48.44 % (F2C) or 26.00 % (T79C), while
the molecular brightness increases from 80636 cpms to 109172 cpms (F2C) or 98512 cpms
(T79C). Similar trends are observed for the flexible cyanine dye AF647 and the Rhodaminebased AF546, which both decreased in QY but increased in molecular brightness upon
conjugation to the protein.
The effect of Trolox is also more interesting at the single molecule level than the
ensemble QY data would initially suggest. For example, as shown above, AF488 in the absence
of Trolox shows a 7.8 fold decrease in QY while the molecular brightness shows a 1.1 – 1.5 fold

96

increase. When Trolox is present in the solution (Table II), the numbers are somewhat different.
The QY decreases from 65.67% to 3.10 % (a 21-fold decrease), while the molecular brightness is
effectively the same. Conversely, in the absence of trolox, Cy3 QY increased from 2.01% to
13.32% (F2C) and 18.01% (T79C), which is a 6.6-9.0 fold increase, while the molecular
brightness increased from 3668cpms to 12172cpms (F2C) or 11635cpms (T79C), which is a 3.23.3 fold increase. However, in Trolox, Cy3 QY increased from 2.65% to 14.95% (F2C) or
22.00% (T79C), a 5.6-8.3 fold increase (similar to the increase without Trolox), while the
molecular brightness increased from 2679cpms to 12579cpms (F2C) or 15683cpms (T79C), a
5.0-6.0 fold increase, which is much higher of an increase than without Trolox. Overall, these
results show that Trolox caused an increase in the “dark fraction” formation of rigid rhodamine
dyes compared to the buffer without Trolox. However, for the flexible cyanine dyes, attachment
to the protein caused an increase in molecular brightness, which was more pronounced in the
presence of Trolox than in its absence.

Fluorescence Lifetimes
Fluorescence lifetime depends on the dye structure, microenvironment and molecular
associations. [69] In particular, it can report on whether any fluorescence quenching that is
present upon conjugation to the protein is dynamic or static. [47] Dynamic quenching will result
in a decrease in fluorescence lifetime concomitant with the decrease in quantum yield while
static quenching will result in no observed difference in fluorescence lifetime. Fig.3 shows
fluorescence lifetime decay curves of CY3 in buffer without trolox (left-side panels) and with
trolox (right-side panels) before and after conjugation to the different protein mutants. The
fluorescent lifetime decay curves for the rest of the dyes are shown in the supplementary
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information (Fig.S2). Table I (without Trolox) and II (with Trolox) collates the average
fluorescence lifetimes for each of the dyes both free and when conjugated to each protein mutant.
In the absence of Trolox, the rigid rhodamine-based dyes of AF488 and AF546 both
show a decrease in fluorescence lifetime upon conjugation to the protein. Free AF488 shows a
lifetime of 4.11 ns, which decreases to 3.10 ns when attached to the F2C mutant. Thus, while the
quantum yield of AF488 decreased by 7.8 fold, the lifetime decreased by only 1.3 fold. This
indicates that the majority of the fluorescence quenching is due to static quenching rather than
dynamic. A similar result is observed for AF546, with a slight decrease in lifetime from 3.89 ns
to 3.36 ns (1.15-fold decrease) upon conjugation to the protein, while the quantum yield showed
a much larger 9.7-fold decrease.
In contrast, flexible cyanine dyes showed a drastic increase in fluorescence lifetimes
upon conjugation to the proteins. This is concomitant with an increase in the QY of the dye upon
conjugation. For example, Cy3 showed an increase in fluorescence lifetime from 0.31 ns to 1.10
ns (F2C) or 1.23 (T79C) – a factor of 3.5 – 4.0 increase, while the QY increased by a factor of
6.6 (F2C) – 9.0. It is known that the low QY of flexible cyanine dyes in solution is due to cistrans isomerization, which is presumably reduced upon conjugation to the protein – a process
known as protein induced fluorescence enhancement (PIFE). [70] However, the fact that the QY
increased by a larger factor than the lifetime, suggests that some static quenching may still be
occurring when on the protein. Other flexible cyanine dyes show similar increased lifetimes,
with the exception of AF647, which showed a decrease in QY (1.6 (T79C) – 2.5 (F2C) fold) but
a slight increase in the fluorescence lifetime ((1.1 (T79C) – 1.4 (F2C) fold), indicating formation
of a high “dark fraction” with static quenching. The rigid cyanine dye, Cy3B, showed similar
behavior to the flexible AF647. The QY decreased from 84.94% to 64.20% (F2C) or 65.22%
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(T79C), a 1.3 fold decrease, while the fluorescence lifetime remained the same (2.56 for free dye
vs 2.60 ns in T79C) or increased slightly from to 2.81 ns in F2C, a 1.1 fold increase. Again, this
implies that, upon binding to the protein, primarily static quenching occurs.
Lifetimes were different in the presence of trolox compared to measurements in the
absence of trolox. For example, AF488 rigid rhodamine lifetime in the absence of trolox
decreased from 4.11ns to 3.10 ns (F2C) by 1.33 fold while in the presence of trolox, it decreased
from 3.99 ns to 2.28 ns by a 1.75 fold. This showed that trolox caused some dynamic quenching
of the rhodamine dyes. Other rhodamine dyes showed a similar behavior. Flexible Cy3 dye
behaved in a different manner to rigid rhodamine in that its lifetime in the absence of trolox
increased from 0.31ns to 1.10ns (F2C) and 1.23ns (T79C) which is a 3.5-4.0 fold while, in the
presence of trolox it increased from 0.40ns to 1.35ns (F2C) and 1.58ns (T79C) which is a 3.4-4.0
fold. These results indicated that trolox had no significant effect on the lifetimes of flexible
cyanine dyes since the increase was similar in both conditions. Other flexible and rigid cyanine
dyes had similar behaviors.
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Figure 3. Fluorescence lifetime decay curves of free CY3 dye vs their respective labeled hFGF1
mutants (F2C and T79C). Panel a1) on the left side is a measurement carried out in “no trolox”.
Panel a2) on the right side is a curve measured in “trolox”. Labeled WT-hFGF1 was not
determined because unlike the mutants, it exhibited low labeling efficiency due to non-specific
labeling, as the three native cysteine are buried with the barrel shape and are not easily accessible
to the maleimide moiety of the dyes. Lifetimes obtained from these curves are shown in
paranthesis and compared with other photophysical parameters in table I & II and Fig 4.

Comparison of Photophysical Parameters
In this section, we compare the photophysical parameters of ensemble quantum yield
(QY), fluorescence lifetimes, molecular brightness (ꜪFCS, ꜪPCH) and number of fluorescent
molecules in the observation volume (NFCS, NPCH) as summarized in the bar graphs in Fig.4.
Further, the measured concentration (conc. (nM)) used for collecting the fluorescence traces for
fitting FCS and PCH are also shown. The bar graphs were constructed using table I (“no trolox”)
and II (“trolox”) whereby, the photophysical parameters of the fluorescently labeled proteins
(WT-hFGF1, F2C-hFGF1 & T79C-hFGF1) were divided by their respective free dyes, in order
to get the ratios for comparison. The graphs are expressed as the ratio (y axis) of each
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photophysical parameters of free dyes, relative to their respectively labeled proteins. For
measurements concerning fluorescently labeled WT-hFGF1, only the molecular brightness was
measured as control to observe the behavior of wildtype non-specific labeling compared to site
specific labeling of mutants at single molecule level. This information was particularly useful for
the protein mutants that had low site-specific labeling efficiency (below 50 %, see table I & II)
since, the changes in the photophysical parameters for such proteins would be significantly
influenced by non-specific labeling.
When analyzing the “no trolox” measurements shown in Fig. 4a, the blue rigid structured
rhodamine-based dye of AF488 showed a significant ~8x decrease in the ensemble QY, when
bound to F2C-hFGF1 while, the yellow dye of AF594 showed a ~16x decrease on the same
mutant position. For the single molecule detection techniques of FCS and PCH, the measured
concentration (conc.(nM)) for WT-hFGF1-AF488 and F2C-hFGF1-AF488 were ~3x and ~8x
higher than that of free dye respectively. Conversely, the molecular brightness of WT-hFGF1AF488 and F2C-hFGF1-AF488 showed no significant changes compared to the free dye because
WT-hFGF1-AF488 and F2C-hFGF1-AF488 respectively only decreased their brightness by
~1.4x and ~1.5x. In addition, the lifetimes of F2C-hFGF1-AF488 also showed a ~1.3x decrease
relative to the dye. A similar trend in the behavior of the molecular brightness was also observed
for green dyes of AF546 and CY3B and their respective labeled proteins. However, the only
difference was that the ensemble QY of CY3B on the proteins was not as significantly quenched
like the rhodamine dyes. This was also supported by the fact that CY3B and its labeled proteins
used the same conc. (nM) in order to maintain 104-105 photon counts range needed for FCS and
PCH studies. In “trolox” (Fig. 4b), all these rigid structured dyes behaved the same as observed
in “no trolox” conditions, except that “trolox” quenched the ensemble QY of these rigid dyes but
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not their brightness and lifetimes. Overall, the results showed that for the labeled proteins with
significant quenching of ensemble QY (AF488 & AF546), their measured conc.(nM) for PCH
and FCS studies needed to increased high enough in order to capture the one fluorescent
molecule which, had similar brightness and lifetimes to free dyes. Further, this type of behavior
implied that there was a large fraction of dark states due to static quenching occurring on the
fluorescently labeled F2C position. In addition, the results also indicated that fluorescently
labeled proteins with rigid cyanine dye of CY3B, did not experience much quenching like the
rhodamine dyes as it relative maintained its photophysical properties between the free dyes and
mutants.
Comparison studies of the flexible green cyanine dyes of CY3 and SulfoCY3 showed a
significant increase in the ensemble QY, molecular brightness and lifetimes when conjugated to
the proteins. For example, in “no trolox” labeled proteins with CY3 increased in ensemble QY
by ~7x and ~9x on F2C-hFGF1-CY3 and T79C-hFGF1-CY3 respectively. Further, molecular
brightness of WT-hFGF1-CY3, F2C-hFGF1-CY3 and T79C-hFGF1-CY3 all increased by ~3x
relative to the free dyes. A similar observation was made for SulfoCY3 and its labeled proteins
since ensemble QY and brightness were also increased drastically. Lifetime measurements of
free CY3 and SulfoCY3 also increased by ~3x to 4x on all fluorescently labeled proteins when
compared to their free dyes. For the red fluorescent dyes of AF647, CY5 (flexible cyanine) and
IF647 (unknown structure), they showed an overall similar photophysical behavior to the green
flexible cyanine dyes although, there were some slight differences. For example, in “no trolox”,
ensemble QY of site-specifically labeled F2C-hFGF1-IF647 and T79C-hFGF1-IF647 increased
by ~8x and 11x respectively, relative to the free dyes. Moreover, in comparison to the free dye,
molecular brightness of these two mutants increased by ~2x and 3x respectively, from the FCS
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data. WT-hFGF1-IF647 also increased by ~2x compared to the free dyes. Fluorescence lifetimes
of both mutants also increased by ~2x relative to the free dyes. However, amongst the labeled
proteins, mutant T79C-hFGF1-IF647 position exhibited the highest increase in all photophysical
parameters. Similar behaviors were also observed for the other red dye CY5 and its labeled
protein. The AF647 fluorescent dye showed somewhat of a different trend because the lifetime
of free dyes and labeled proteins were similar, but the labeled protein ensemble QYs slightly
decreased while the molecular brightness increased by ~2x when conjugated to the proteins. In
“trolox”, all the red dyes also exhibited similar behaviors except that “trolox” seemed to quench
the ensemble QYs in some of the samples. Overall, the green and red flexible cyanine-based
dyes and IF647 increased their photophysical behavior upon being conjugated to the proteins.
In summary, there was no significant change in the photophysical parameters of the free
dyes and fluorescently labeled proteins for the rigid structured dyes (AF488, AF546 and CY3B)
at the single molecule level. However, the ensemble QYs of AF488, AF546 and AF594
decreased drastically when bound to the F2C position while that of CY3B was not significantly
quenched. On the contrary, cyanine-based dyes and IF647 experienced a drastic increase in their
photophysical properties at both the single molecule and ensemble level. A comparison of both
classes of dyes revealed that the rigid structured dyes were only affected significantly by the
protein at the ensemble level, but not at the single molecule level. On the other hand, flexible
dyes and IF647 were affected at both levels by the protein, since they experienced a large protein
induced fluorescence enhancement particularly with T79C position. Amongst the cyanine dyes,
we also observed that rigid cyanine of CY3B behaved differently from its flexible cyanine
counterparts. The results also showed that “trolox” seemed to mostly affect the ensemble QYs
for some dyes, but it did not necessarily affect the dyes at the single molecule level.
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Figure 4. Comparison of photophysical properties of fluorescently labeled hFGF1 wildtype
(WT-hFGF1) and mutants (F2C-hFGF1 & T79C-hFGF1) relative to free dyes. The bar graph
was constructed using the data for each parameter from tables I (no trolox) and II (trolox). The
ratios were obtained by dividing each parameter of the respective labeled proteins by their
corresponding free dyes. Panel a) shows the comparison of “no trolox” parameters and Panel b)
is the “trolox” parameters.
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Discussion
The bar graph of Fig.4 will be used for the discussion section because it clearly
summarizes and compares the photophysical parameters between free dyes and their labeled
proteins. Overall, analysis of the rigid structured rhodamine dyes of AF488, AF546 and AF594
compared to when conjugated to F2C-hFGF1 indicated that the presence of amino acids of the
proteins were drastically quenching fluorescence. Quenching can either be static or dynamic or a
combination of both [71], occurring at different degrees. Lifetime measurements are a definitive
method commonly used to distinguish between the two types of quenching because they only
reveal dynamic quenching also known as collisional quenching [47, 72]. This type of quenching
occurs when the quencher interacts with the population of the fluorophore in their excite state,
resulting in non-radiative decay. On the other hand, static quenching occurs when there is a
strong coupling between the quencher and fluorophore which results in a ground state complex
formation that is also non fluorescent as it cannot be excited [71, 72]. Thus, lifetimes analysis of
free rhodamine dyes (AF488 & AF546) and their labeled F2C-hFGF1 indicated that the
fluorophores exhibited predominantly static quenching when conjugated to the protein because
they had very similar lifetimes. However, there was also slight decrease in the lifetimes which
indicated that there was also a small fraction of dynamic quenching. In addition, the presence of
large fraction of dark states was supported by the fact that free dyes and labeled F2C-hFGF1 had
similar molecular brightness when the concentration of labeled protein was increased ~8x. This
led to the conclusion that approximately one in eight (1 in 8) molecules had a similar
fluorescence to the free dye and that the rest of the molecules were dark fractions. The control
experiments of molecular brightness of labeled WT-hFGF1 with these rigid dyes indicated that
there was no significant difference between free dyes, non-specific or site-specifically labeled
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proteins. However, site-specifically labeled protein is still preferred in single molecule detection
studies such as smFRET assays since they have very high labeling efficiency unlike non-specific
labeling. Contrary to these rigid rhodamine dyes, the rigid cyanine of CY3B, was not
significantly statically or dynamically quenched by the presence of amino acids upon
conjugation to the protein. This was because the free dye and labeled proteins had similar
lifetimes while its ensemble QY was also not significantly quenched. Further, this can be
attributed to the amino acids forming less non fluorescent statically quenched complexes with
this dye compared to the rhodamine dyes. Also, using CY3B, we can infer that neither nonspecific positions of wildtype nor F2C and T79C site-specific positions had a large effect on the
overall bright fraction of the rigid structured probes, as long as they were not statically quenched.
Several mechanisms and quenchers are responsible for the quenching trend exhibited by
these rigid structured rhodamine-based dyes. It can be difficult to decipher the exact mechanism
of quenching but typical ones commonly responsible will be discussed. The universal quencher
almost in all fluorophores whether as free dyes or when conjugated to proteins is paramagnetic
oxygen dissolved in buffers (µM to mM), as it makes fluorophores to visit the triplet state via
intersystem crossing and cause severe blinking [22, 73]. Triplet state blinking is a nuances
because the triplet state persists for longer timescales of milliseconds that are longer than
fluorescence timescale [22, 74]. Therefore, for our discussion, contribution of oxygen to
quenching will be ignored and the focus will be on the effect of the protein on the probe, either
acting as a fluorescence quencher or enhancer.
Amino acids of proteins covalently linked to rhodamine dyes have intramolecular
interactions and they are known to cause static quenching via strong contacts between aromatic
residues and the dye. The protein of hFGF1 has one tryptophan (W), five phenylalanine (F) and
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seven tyrosine (Y) [75] which can form hydrophobic and van der waals contacts with the
rhodamine backbone to form a ground state non-fluorescent complex [76, 77]. Intramolecular
photoinduced electron transfer (PET) is another predominant cause of quenching that can occur
whereby, there is an electron transfer between a donor and acceptor during the excited state
which, results in a complex that is non-fluorescent upon return to the ground state [78, 79].
Tryptophan is one such amino acid notorious for quenching rhodamines as it is a good electron
donor while the rhodamine acts as an acceptor [77]. Electron exchange quenching can also occur
whereby, the donor has an electron in its lowest unoccupied molecular orbital (LUMO) and is
transferred to the highest occupied molecular orbital (HOMO) of the acceptor [71]. However, the
same electron can be returned back to the donor leaving the acceptor (rhodamine in this case)
with a semi oxidized radical cation or vice versa if the amino acids acted as electron acceptors.
Charged residues can also act in this manner as either donors or acceptors and hFGF1 being an
acidic protein, can significantly quench the fluorophores. For instance, hFGF1 has charged acidic
residues of nine glutamic acids (E) and seven aspartic acids (D) and charged basic residues of
eleven lysines (K), six arginines (R) and five histidines (H) [75]. The F2C position that hosts the
rhodamine probe is also on a flexible N terminal unstructured loop that is very dynamic and can
interact with the amino acids and cause static quenching [9]. Small fraction of dynamic
quenching observed could be due to amino acids diffusing closer to the fluorescent fraction (1 in
8 molecules) during the excited state hence, the slight decrease in lifetimes observed when
compared to free dyes. Trolox can also cause quenching as seen in the “trolox” measurements
because although, it depopulated the triplet state (T1) by redox reactions, at high concentrations,
it can undergo redox reactions with the fluorescent singlet excited state (S1) [22]. This tends to
diminish fluorescence since trolox is now also depopulating the singlet state and, this could be
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the case in our experiments as we used 2mM concentration. However, this decrease of QY by
“trolox” was not of great concern because we are only concerned with comparative studies of
free dye behavior relative to when conjugated to the protein. In addition, we used a concentration
typically used in single molecule detection studies [80].
For the flexible cyanine dyes of CY3, SulfoCY3, CY5 & IF647 there was an overall
drastic increase in ensemble QY, molecular brightness and lifetimes due to enhancement of
fluorescence by the site-specifically labeled F2C-hFGF1 and T79C-hFGF1. This increase was
also seen on fluorescently labeled mutants of IF647 although, its structure is not known. These
results indicated that there was no intramolecular static nor dynamic quenching of the probes by
the amino acids but rather, there were other factors contributing to the increase in the
fluorescence. Two of the main factors could be the fact that these dye are greatly affected by
viscosity and degree of flexibility of the dyes between their free state and conjugated states [29,
81]. Free cyanine dyes are notorious for exhibiting low fluorescence since their high flexibility
and viscosity undergo photoisomerization from the fluorescent “trans” isomer to the triplet state
non-fluorescent “cis” isomer [29, 82, 83]. Photoisomerization is caused by bond rotation of the
polymethine chains upon excitation due to the bond twisting and bending which, have a low
activation energy compared to the ground state [82]. However, these dyes are still commonly
used because their fluorescence become significantly increased when their flexibility and
viscosity decrease upon being conjugated to the proteins which favors the fluorescent “trans”
isomer. This behavior of protein induced fluorescence enhancement [70] was clearly one of main
contributing factors to the drastic increase in the photophysical parameters observed. On the
other hand, photoisomerization is not observed for rigid structured rhodamine (AF488, AF546)
and rigid cyanine dyes (CY3B) because they have rigid π electron conjugated structures with
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bonds that cannot twist and turn to favor non-fluorescent isomers [71, 84]. To summarize, the
flexible dyes and IF647 experienced high protein induced fluorescence enhancement due to
reduced photoisomerization when conjugated to the protein while, rigid structures were not
affected by this change of isomers during their excitation.
The positioning of the probes on the proteins also played a critical role on their behavior
particularly, on the flexible cyanine dyes but not so much on the rigid dyes. For instance, in “no
trolox”, T79C-hFGF1-IF647 increased ensemble QY (~11x), brightness (~3x) and lifetimes (2x)
drastically compared to F2C-hFGF1-F647 which respectively increased ensemble QY,
brightness and lifetimes by ~8x, ~2x and ~2x. This is explained by the fact that T79C position is
on a rigid bend region between β strand 7 and 8 which, further makes the polymethine chain to
have less flexibility, viscosity and bond rotation thus, increasing fluorescence. However, for the
F2C position, the fluorescence is not enhanced to a similar degree as T79C position because, it is
located on the highly flexible unstructured region of the N terminal which, does not decrease the
dyes flexibility as much. In addition, F2C position did not label well with most of these cyanine
dyes which, could also explain why its increase in fluorescence was not as high as the T79C
position. We also observed that non-specifically labeled wildtype positions also induced
fluorescence of the red cyanine dyes while that was not the case for the flexible green cyanine
dyes. Similar to the F2C position, this is because non-specific labeling of wildtype has very low
labeling efficiency which could also mean that the cyanine dyes flexibility is not drastically
reduced by these positions compared to T79C position. As mentioned above, this is not the case
for the rigid dyes as they were not significantly affected by either wildtype nor F2C or T79C
positions. Overall, we can conclude that only flexible dyes are affected by their labeling sites on
the proteins while the rigid structured dyes are not affected.
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Flexible dyes of AF647 seemed to behave slightly different from the other cyanine
flexible dyes, even though it is an equivalent structure to CY5 thus, was expected to also show
protein induced fluorescence enhancement across all the photophysical properties. However, this
dyes was slightly statically quenched on both T79C and F2C positions while, there was no
dynamic quenching observed on the protein since the lifetimes of free dye and labeled proteins
were very similar. It seems that out of the bright fraction at single molecules level, they had
protein induced fluorescence enhancement from decrease in flexibility and viscosity of AF647
upon being conjugated both non-specifically on WT-hFGF1 and site-specifically on F2C and
T79C positions. A comparison of parameters between the positions reveal that there was not a
significant change in lifetimes and brightness although F2C-hFGF1 was slightly more statically
quenched than T79C labeled protein. In general, AF647 did not behave as expected even though
it is also a flexible cyanine dye with similar properties to CY5.
In summation, the rhodamine dyes (AF488, AF546 and AF594) experienced high degree
of static quenching by the protein but, the bright fraction maintained very similar photophysical
behavior to free dyes. Flexible cyanine dyes (CY3, SulfoCY3 and CY5) and IF647 exhibited
very high protein induced fluorescence enhancement which, was affected by the position of the
probe on the protein and the degree of photoisomerization. Rigid cyanine of CY3B behaved
similarly to rhodamine dyes due to having similar π electron conjugated structures thus, not
behaving like flexible cyanine dyes. From the rigid dye of CY3B that was able to be labeled at
both site-specific positions, we inferred that the position of labeling on the protein did not affect
the behavior of the rigid dyes as long as they were not statically quenched. Surprisingly, AF647
showed some static quenching however, at single molecules there was protein induced
fluorescence enhancement.
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Conclusion
Our findings reveal that when comparing the photophysical properties of labeled proteins
to free dyes in solutions, ensemble QY, molecular brightness and fluorescence lifetimes are
affected in unpredictable ways. These results are interpreted through a combination of rotational
and vibrational degrees of freedom of the probe as free dye and when conjugated to proteins.
Further, local environment of the probe on the protein and its ability to interact with the amino
acids such as aromatic and charged residues affected quenching statically (complex formation) or
dynamically. Our results also showed that ensemble fluorescence studies do not always correlate
to single molecule studies since seemingly low ensemble QYs can still be detected at single
molecules or vice versa. Therefore, wise choice of probe depending on its structure and position
on the protein play a critical role on the photophysics behavior of the dyes and must be taken into
serious account when labeling hFGF1. To conclude, we successfully designed and characterized
fluorescently labeled hFGF1 tracers which span the visible light spectrum of the electromagnetic
spectrum for application in single molecule detection studies such as smFRET.
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Supplementary
Table S1: Standard deviation amongst triplicates QY measurements for free dyes and
fluorescently labeled mutants of F2C-hFGF1 and T79C-hFGF1.
AF488

"No
Trolox"
±0.54

"Trolox"
±0.47

WT-hFGF1-AF488

-

-

F2C-hFGF1-AF488

±0.05

±0.25

CY3

±0.05

±0.55

WT-hFGF1-CY3

-

-

F2C-hFGF1-CY3

±0.21

±0.16

T79C-hFGF1-CY3

±2.64

±0.01

SulfoCY3

±0.31

±0.63

WT-hFGF1-SulfoCY3

-

-

F2C-hFGF1-SulfoCY3
T79C-hFGF1SulfoCY3

±0.36

±4.16

±5.01

±1.25

CY3B

±4.92

±5.97

WT-hFGF1-CY3B

-

-

F2C-hFGF1-CY3B

±4.50

±0.22

T79C-hFGF1-CY3B

±4.67

±1.63

AF546

±1.63

±2.24

WT-hFGF1-AF546

-

-

F2C-hFGF1-AF546

±0.14

±0.37

AF594

±0.47

±2.91

WT-hFGF1-AF594

-

-

F2C-hFGF1-AF594

±0.33

±0.54

AF647

±0.96

±1.14

WT-hFGF1-AF647

-

-

F2C-hFGF1-AF647

±0.88

±1.62

T79C-hFGF1-AF647

±2.21

±1.14

IF647

±0.45

±0.30

WT-hFGF1-IF647

-

-

F2C-hFGF1-IF647

±5.92

±1.94

T79C-hFGF1-IF647

±5.85

±2.03

CY5

±0.27

±2.21

F2C-hFGF1-CY5

±2.87

±1.31

T79C-hFGF1-CY5

±1.34

±1.54

(-) QY of fluorescently labeled WT-hFGF1 was not measured because wildtype labeling is nonspecific.
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Further results from Figure 2.
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Figure S1. FCS and PCH used to extract the average molecular brightness (Ꜫ) and the number of
fluorescent molecules (N) of respective fluoresccent dyes vs labeled hFGF1 (WT, F2C & T79C)
recorded in “no Trolox” (left side panels) and “trolox” (right side panels). Both ACF and PCH
(bin time 50 µs) are plotted from the same fluorescence intensity traces sampled for 2 min.
Panels b1, b2, d1, d2, f1, f2, h1, h2, j1, j2, l1, l2, n1 & n2) are ACFs and Panels c1, c2, e1, e2,
g1, g2, i1, i2, k1, k2, m1, m2, o1 & o2) are PCHs. Molecular brightness (Ꜫ) measured in cpms
using the ACF was calculated by dividing the average photon count intensity (counts/s) from the
traces by the number (N) of fluorescent molecules as determined using Eq.7 & 8. A fit of ACFs
Using the triplet state model leads to random residual distribution as shown below the ACF
curves. Fitting of the one photon excitation PCHs applied first order correction parameter (Fc1)
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Figure S1. (Cont.) while reduced chi-squared (𝜒 2 ) analysis was applied to both ACFs and
PCHs. AF594 measurements could not be determined since we did not have the green or yellow
laser for excitation while T79C-hFGF1 labeled with AF488, AF546 & AF594 is also not shown
as it aggregated during bioconjugation. All the photophysical parameters obtained from ACFs
and PCHs are summarized in table I & II and compared on the bar graph shown in Fig 4

Further results from Figure 3.
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Figure S2. Fluorescence lifetime decay curves of free dyes vs their respective labeled hFGF1
mutants (F2C and T79C). Panels b1, c1, d1, e1, f1, g1 & h1) on the left side are measurements
carried out in “no trolox”. Panels b2, c2, d2, e2, f2, g2 & h2) on the right side are curves
measured in “trolox”. Similar to QY, FCS and PCH studies, T79C-hFGF1 with labeled with
AF488, AF546 & AF594 was not measured because it aggregated during labeling. Labeled WThFGF1 was also not determined because unlike the mutants, it exhibited low labeling efficiency
due to non-specific labeling, as the three native cysteine are buried with the barrel shape and are
not easily accessible to the maleimide moiety of the dyes. In addition, AF594 and its labeled
protein was not measured since we did not have the green and yellow laser for excitation.
Lifetimes compared to other photophysical parameters are shown Fig 4, table I and II.
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IV. Towards Designing smFRET Assays to Study the Regulation of FGF Binding to its
Receptor (FGFR)
Abstract
The binding of fibroblast growth factor (FGF) to its receptor (FGFR) is critical in downstream
signaling events that trigger angiogenesis in fibroblast cells. When homeostasis of this binding is
not regulated due to mishappens such as mutations specifically on the FGFR, this can lead to
unregulated growth which can cause a myriad of cancers. As a result, we aim towards
developing single molecule fluorescence resonance energy transfer (smFRET) assays to reveal
sub-populations and heterogeneity associated with FGF/FGFR binding. Our preliminary results
showed that mutants of the D2 domain of FGFR were successfully synthesized, and site
specifically labeled with fluorescent rhodamine dyes at high labeling efficiency. However,
attempted ensemble FRET assays between binding of FGF1/D2 were not successful. We hope
this preliminary work will provide a foundation for the design of smFRET assays since there are
many single molecule events such as binding distances, structural dynamics and conformational
changes which can be explored.
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Introduction
Fibroblast growth factors (FGF) play an important role in the physiological signaling
processes such as cell proliferation, wound healing and embryonic development. [1, 2] The
binding of FGF to its receptor (FGFR) requires the molecule of heparin while downstream
signaling is triggered upon dimerization of two FGF-FGFR-heparin complexes on the plasma
membrane. [3] FGFR is a tyrosine kinase receptor composed of the extracellular domains of D1,
D2 and D3 and negatively charged acid box (AB) linker between D1 and D2. [4, 5] In addition,
it has a transmembrane helix domain and intracellular tyrosine kinase domain which becomes
phosphorylated upon dimerization of two FGF-FGFR-heparin complexes.[5] Specifically,
binding of FGF to FGFR is confined mainly to the D2 domain and a small portion of the D3
domain. However, unregulated FGF-FGFR signaling causes excessive cell proliferation which
leads to cancer. [6, 7] For this reason, it has become critical to understand the binding kinetics of
FGF/FGFR and the regulation of FGFR, as this knowledge is valuable in developing therapies of
cancer and skeletal disorders.
Binding constant or association constants (Kd) reveal the strength of the binding affinity
between ligand-molecule complexes.[8, 9] Particularly, understanding binding events between
FGF1 ligand and FGFR has been used to study skeletal disorders such as Kallmann Syndrome
(KS) caused by mutations in the D2 domain of FGFR which weakens binding to FGF1. For
instance, isothermal titration calorimetry (ITC) results by Thurman, R.D and co-workers [10]
showed that mutation A168S of D2 domain related to KS caused a 10-fold decrease in binding
affinity to SOS (heparin analog) and a total loss of binding to wildtype-FGF1 (wt-FGF1)
compared to wildtype D2 (wt-D2). Specifically, the results showed that the Kd of D2A168C/SOS (22 µM) and D2-A168C/wt-FGF1 (no binding) were much weaker compared to the
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respective wt-D2/SOS (2.2 µM) and wt-D2/wt-FGF1 (2 µM) values. SOS stands for sucrose
octasulfate, and it is a monodispersed analog of heparin commonly preferred in experiments over
the polydisperse heparin. [11] In addition to this study, another study by Hung K.W and coworkers [12] reported wt-D2/wt-FGF1 Kd values of 65 nM in the absence of SOS and 20 pM in
the presence of SOS. The discrepancy of the Kd values between the two studies could be due to
the differences in the sensitivity of the ITC instruments. Nevertheless, these two studies provided
a starting point for developing FRET assays in terms of which concentrations to use for our
experiments. Although, ITC is capable of revealing the stoichiometry, kinetics (Kd) and binding
enthalpy [13, 14] of D2/FGF complex formation, it does not reveal heterogeneity associated with
the sequence of binding events since it is an ensemble technique.
Single molecule fluorescence resonance energy transfer (smFRET) is one such powerful
and sensitive technique capable of revealing hidden heterogeneity and subpopulations within
binding protein partners.[15, 16] FRET is exhibited when a respective protein partner labeled
with a donor fluorescent dye transfers its non-radiative energy to its acceptor protein binding
counterpart within a distance of 10-100 Å. [17, 18] Since smFRET is a distant dependent
technique, it can be used as a molecular ruler [19] which, is more accurate than relying only on
Kd values to reveal association events. Further, ensemble FRET can also determine Kd values
which can be corroborated with those obtained by ITC, in order to conclusively assign binding
constants. For example, ensemble and smFRET could be carried out between D2 mutants related
to KS and FGF by labeling the D2 with a donor dye and FGF with the acceptor dye or vice versa.
These studies can also be carried out in the presence or absence of heparin in order to determine
its role in D2/FGF1 binding related to diseases which can help in drug development.
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Fluorescent labeling of protein partners for FRET assays is commonly carried out by the
use of small organic dyes functionalized with maleimide moiety which bind to cysteine residues
of the proteins via a strong covalent thioether bond. [20, 21] This strategy is preferred because
cysteines are rare and therefore, the degree of labeling of the protein can be controlled with high
accuracy. [22] Further, proteins such as D2 domain which do not contain free cysteine residues
can be mutated to cysteine at specific sites via site directed mutagenesis. With the aim towards
developing ensemble FRET assays followed by smFRET assays, the first objective was to carry
out site directed mutagenesis and protein purification of the D2 domain and FGF1 mutants.
Wildtype FGF1 has 3 native cysteines but they do not label because they are buried within the
trefoil barrel hence, the need for site specific labeling. [23] Similarly, D2 domain does not have
free cysteines which can be labeled since its only two native cysteines are involved in a
disulphide bond important in maintaining the tertiary structure of the protein. As a result, D2
domain was singly mutated at residue 3 (Ser to Cys) and residue 56 (Glu to Cys) while FGF1
was singly mutated at residue 2 (Phe to Cys) and residue 79 (Tyr to Cys) from as already shown
in our submitted manuscript. Once these mutant proteins were purified, the second objective was
to fluorescently label them with an array of dyes to act as either donor or acceptor depending on
the dye behavior on D2 and FGF1. The third objective was to carry out ensemble FRET assays
between D2 domains and FGF based on the electrostatic interactions followed by smFRET
assays. Figure 1 shows the designed mutants on D2 and FGF1 and static distances between the
two proteins as the distances were useful in inferring whether efficiency of FRET will occur.
[24] Super FGF1 (sFGF1) mutant (under propriety) was also fluorescently labeled but site
directed mutagenesis to cysteine residues was not carried out. This mutants had mutations that
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were designed by Kumar group to increase the stability of FGF1 however, we found that its new
conformational changes exposed the native cysteines for fluorescent labeling.
Our results indicated the S3C-D2, E91C-D2 and E56C-D2 were successfully synthesized
and that the refolding step of S3C-D2 was successful since it was denatured during purification.
Further, the results showed that the novel non-denaturing purification protocol of D2 using the
Rd tag was also successful although it required further optimization. Fluorescent labeling of
S3C-D2 with AF488 and AF546 showed high labeling efficiency of 89 % and 52 % respectively,
as they acted a donors during the preliminary ensemble FRET assays with FGF1. The sFGF1
also labeled with high efficiency of 100 %. For photophysical characterization of site specially
labeled FGF1 mutants (F2C-FGF1 and T79C-FGF1), see chapter 3. However, preliminary
ensemble FRET assays of S3C-D2-AF488/F2C-hFGF1-AF594 and S3C-D2-AF546/F2ChFGF1-AF647 were not successful and requires further optimization such as change of buffer
ionic strength and choice of dyes. Overall, these preliminary data will be useful to the
continuation of this project towards designing smFRET assays.
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Q67C-D2
S3C-D2

E56C-D2

Heparin
D3 domain

F2C-FGF1
(F2C)

Figure 1. Ribbon structure of acidic hFGF1 complexed with ectodomain of FGFR2 and heparin.
Yellow ruler measurements are in angstroms (Å) to illustrate the various FRET assays that can
be carried out between singly mutated D2/FGF1. Color coding and site directed mutagenesis
from the original structure (PDB ID: 3OJM) was carried out using pymol. Structure of hFGF1
(green) shows the positions of F2C mutants (cysteines are shown in cyan) while heparin as
sticks. D2 domain is shown in blue while D3 domain is shown in brown. The purple, yellow, red
and orange on both D2 and D3 indicates FGF and heparin binding sites.

Materials and Methods
Site directed mutagenesis, Overexpression and Purification of D2 and FGF1 mutants
The wt-FGF1 and wt-D2 pET plasmids were mutated using PCR to yield F2C-FGF1,
T79C-FGF1, S3C-D2, E91C-D2 and E56C-D2 and verified by DNA sequencing. The proteins
were overexpressed in BL-21DES PLys cells from E.coli (Novagen) grown in Luria broth. The
overexpression conditions were carried out by shaking at 37˚C and 200 rpm until the OD600
reached 0.6 whereby Isopropylthio-β-D-galactoside (IPTG, 0.5mM/L) was added to induce
growth. Shaking continued until the OD600 reached 0.6 after which the cells were centrifuged at
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6000 rpm for 20 min in order to obtain pellet. Mutants of FGF1 pellet were suspended in 10 mM
phosphate (PBS) buffer (pH 7.2) and lysed by sonication at 1 sec pulses for 55 pulses after which
the cell debris was removed by centrifugation at 19,000 rpm for 30 min. A heparin affinity
column was used for purification of the FGF1 mutants which were then eluted by gradient of 0.2
M to 1.5 M of NaCl2. All D2 mutants had a 6X His tag while E56-D2 also had a fusion tag of
Ruby (Rd) (under propriety) and as a result, they were all purified using Nickel (Ni2+) affinity
column and eluted with imidazole gradient (250-500 mM). However, formation of inclusion
bodies of S3C-D2, E91C-D2 required the mutants to first be denatured in 8 M urea followed by
on-column refolding during the gradient elution. On the contrary, the Rd on E56C-D2 mutant
prevented the formation of inclusion bodies hence purification of this mutant was by nondenaturing conditions followed by heat treatment (60-75 ºC) and cleavage of the Rd fusion tag
by TEV protease. SDS-PAGE was used to analyze for the purity of proteins while UV/Vis and
Fluorescence spectroscopy were used to analyse concentration and global folding.

Fluorescent labeling of D2 and FGF1 mutants
F2C-FGF1 and T79C-FGF1 mutants fluorescently labeled with an array of fluorescent
dyes that span the visible light spectrum as previously described in chapter 2. However, only
F2C-FGF1 labeled with AF594 and AF647 acceptor dyes are relevant for the attempted
preliminary ensemble FRET studies. Similarly, only S3C-D2 mutant was fluorescently labeled
with AF488 and AF546 donor dyes for the FRET assays while labeling of the other synthesized
mutants need to be done in the future. Fluorescent labeling conditions of the S3C-D2 mutant was
similar to that of the FGF1 labeling as described in chapter 2.
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Ensemble Fluorescence Resonance Energy Transfer (FRET) Assays
Preliminary ensemble FRET measurements were carried out on PerkinElmer LS 55
luminescence spectrometer. The FRET experiments were carried out in a reaction buffer
containing 10 mM PB, 100 mM NaCl and 50 Ammonium Sulphate (pH 7.2) with a magnetic
stirrer for mixing. The normal design of binding experiments is to set the donor concentration at
10x of the Kd while the acceptor concentration should be up to 20x of the donor concentration.
This is to ensure that the donor does not become the limiting factor in Kd measurements as the
acceptor saturates and becomes independent of the donor concentration for the maximum FRET
to be obtained. However, due to concentration limitations, the donor was instead set at ~ 5x (300
nM) the Kd while the acceptor was 13x (4096 nM) the donor concentration of 300 nM. For the
S3C-D2-AF488/F2C-FGF1-AF594 FRET pair, excitation of the sample was at 470 nm and
emission collection was at 480 to 700 nm. Excitation of S3C-D2-AF546/F2C-FGF1-AF647 was
at 545 nm while collection of emission was at 555nm to 700 nm. Efficiency of energy transfer
(E) was measured using the relative fluorescence intensity of donor peak in the presence (FDA)
and absence (FD) of the acceptor in order to use the equation of E = 1 – (FDA/FD). [25]

Results
Expression, purification & characterization of FGF1 and D2 mutants
Purified F2C-FGF1 was previously shown in chapter 2 to have a molecular weight of ~17
kDa and to be globally folded. For the D2 mutants of S3C and E91C purified with Ni2+
chromatography, Figure 2A and 2B showed that the mutant proteins were pure as both had
molecular weight of ~14 Da. The E65C-D2 mutant also purified with Ni2+ column followed by
cleavage of the Rd tag is shown in Figure 2C and, it can be seen that the E56C-D2-Rd was ~23
kDa before cleavage while E56C-D2 was ~14 kDa after cleavage. These results indicated that
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TEV was successful in the cleaving of the Rd and that the protein was pure. sFGF1 obtained
from our collaborator also showed a band at ~ 17 kDa as shown in Figure 2D. Since only S3CD2 mutant was analyzed for global folding, Figure 3 showed absorbance and emission maxima
peaks of ~280 nm and ~335 nm respectively for this mutant. Aromatic residues of proteins are
commonly used to analyze global folding and the absorbance spectra indicated no aggregation
due to lack of sloping of the baseline. In addition, the concentration obtained for the D2 mutants
using beer lamber law was in the range of 50 to 100 µM per liter. Fluorescence emission of the
aromatic residues also showed that the protein was properly folded since a larger stokes shift
would have been observed when unfolded.
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Figure 2. SDS-PAGE analysis of D2 mutants after expression in E.coli and purification with
Ni2+ affinity chromatography. Molecular maker in all gels is denoted by M. Panel A) Lane 1
shows S3C-D2 at ~14kDa. Panel B) Lane 1 represents E91C-D2 at ~14kDa. Panel C) Lane 1
shows E56C-D2-Rd at 23kDa while lane 2 indicates E56C-D2 after cleavage of Rd at ~14kDa.
Panel D) Lane 1 shows sFGF1 ~17kDa.
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Figure 3. Protein folding of S3C-D2 after purification. Panel A) UV spectra showing maximum
absorbance at 278 nm. Panel B) Fluorescence spectra of the proteins exhibiting maximum
emission at 309 nm. Excitation was at 280 nm in 10 mM PBS buffer.

Labeling efficiency of fluorescent Probes to FGF1 and D2 mutants
F2C-hFGF1 and T79C-hFGF1 mutants were fluorescently labeled with an array of dyes
that span the visible light region of the electromagnetic spectrum and characterized for labeling
efficiency as previously our previously submitted manuscript. The S3C-D2 mutant was
fluorescently labeled with AF488 and AF546 so as to act as FRET pairs with F2C-hFGF1
fluorescently labeled with AF594 and AF647 respectively. Figure 4, 5 & 6 shows the respective
chromatography separation of labeled S3C-D2-AF488, S3C-D2-AF594 and sFGF1-AF594 from
excess dye, as well as the UV/Vis spectra used to determine their labeling efficiency. S3C-D2AF488, S3C-D2-AF594 and sFGF1-AF594 had respective labeling efficiency of 89 %, 52 % and
100 %. The high degree of labeling of the S3C-D2 mutant was indicative of site-specific labeling
of by the dye since it was completely folded. sFGF1 was also completely labeled at 100 %
indicating that one or more of the free cysteine resides usually buried within the barrel in wtFGF1, was exposed for labeling.
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Figure 4. Efficiency of S3C-D2 labeling by AF488. Panel A) Size exclusion chromatography
column after labeling of S3C-D2 with Alexa-488. Panel B) Picture showing the labeled and free
fractions. Panel C) UV/Vis spectra of fluorescently labeled unlabeled S3C-D2, AF488 and S3CD2-AF488.
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Figure 5. Efficiency of S3C-D2 labeling by AF546. Panel A) Size exclusion chromatography
column after labeling of S3C-D2 with Alexa-546. Panel B) Picture showing the labeled and free
fractions. Panel C) UV/Vis spectra of fluorescently labeled unlabeled S3C-D2, AF546 and S3CD2-AF546.
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Figure 6. Efficiency of S3C-D2 labeling by AF546. Panel A) Size exclusion chromatography
column after labeling of S3C-D2 with Alexa-546. Panel B) Picture showing the labeled and free
fractions. Panel C) UV/Vis spectra of fluorescently labeled unlabeled S3C-D2, AF546 and S3CD2-AF546.

Preliminary Ensemble FRET Assays
Preliminary ensemble FRET assays between the D2 domain and FGF1 protein were
attempted however, they were not successful. The FRET curve shown in Figure 7A for S3C-D2AF488 and F2C-FGF1-AF594 pair indicated the absence of FRET since the donor emission at ~
525 nm did not decrease. Emission of acceptor (~ 617 nm) seen at higher concentration of 1024
nM to 4092 nM was due to direct excitation and not from FRET since the donor absorbance and
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acceptor absorbance have a slight spectral overlap. In addition, the S3C-D2-AF546 and F2CFGF1-AF647 pair also did not show any FRET as can be seen on Figure 7B. The donor emission
at ~ 573 nm did not decrease while the acceptor at ~ 665 nm did not increase.
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Figure 7. Fluorescence spectrum of preliminary ensemble FRET assays between D2 and FGF1
D2 acted as the donor and had a concentration of 300 nm while the titration of FGF
concentrations was from 0 to 4092 nM. Panel 1) FRET assays between S3C-D2-AF488 and
F2C-D2-AF594 and Panel 2) FRET assay between S3C-D2-AF546 and F2C-D2-AF647.
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Discussion
The main results in this preliminary work is that the mutants of S3C-D2 and E91C-D2
were successfully purified using the denaturing conditions and that the refolding of the protein
was also successful for the analyzed S3C-D2. However, the challenge with this purification
approach was that it was very tedious and yielded protein stocks of very low concentration,
which then required frequent purification. This was particularly distressing since, the size
exclusion chromatography step during labeling further dilutes the protein which then restricts
flexibility in the working concentration of the D2 donor that can be used during ensemble FRET
studies. Low protein concentrations also meant that repeatability of experimental trials was
limited without the need for constant purification. The loss of protein during purification is from
the fact that the predominantly hydrophobic D2 goes into inclusion bodies during expression.
Further, the denatured protein aggregated severely during on-column folding hence the low yield
obtained. To mitigate the issues of denaturing purification, the Kumar group developed a nondenaturing approach which used the Ruby (Rd) fusion tag that minimizes the formation of
inclusion bodies. Hence, the preliminary results of purified Rd-E56C-D2 showed that the TEV
was successful in cleaving the protein from the tag to produce pure and high yield protein.
However, this protocol still requires extensive optimization of the heat treatment step and
kinetics of the cleavage step by the TEV enzyme. Regardless, these results still provided
valuable information about the need to optimize purification protocol. In addition, the intrinsic
fluorescence revealed that mutants did not alter global folding of S3C-D2.
S3C-D2 was able to be fluorescently labeled with donor dye of AF488 and AF546 with
high efficiency of 89 % and 52 % because this position 2 is located on the flexible loop of the N
terminal making it highly exposed to the solvent. In addition, the high labeling efficiency is due
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to the fact that rhodamine dyes of AF488 and AF546 are sulfonated which increases their
solubility in aqueous buffer used during labeling. Similar high labeling efficiency were also
observed on the F2C-FGF1 labeled on the flexible unstructured N terminal loop at position 2
whereby labeling efficiency was above 50 % as shown in chapter 2. sFGF1-AF594 also showed
high degree of labeling efficiency of 100 % due to the fact that the mutations done by the Kumar
group exposed one or more of the native cysteines which are commonly buried with the barrel of
the wildtype. Nevertheless, these results were important in showing that S3C-D2 mutant labeled
with dyes and more dyes needed be explored. Further, they also showed that sFGF1 structural
conformation exposed the native cysteines since neither of its mutations were cysteines.
Attempted preliminary ensemble FRET showed no FRET and there are many possible
reasons for this occurrence. It could be that the quantum yield of the dyes on the D2 donors were
too low for efficient transfer of energy to the FGF1 acceptor. Further, the buffer conditions may
need to be adjusted in order to enable the D2 and FGF1 to have stronger electrostatic interaction.
The normal design of binding experiments is to set the donor concentration at 10x of the Kd
while the acceptor concentration should be up to 20x of the donor concentration. This is to
ensure that the donor does not become the limiting factor in Kd measurements as the acceptor
saturates and becomes independent of the donor concentration for the maximum FRET to be
obtained. For our FRET assays we designed our experiments using Kd of 65 nM from the ITC
reported by Hung K.W and co-workers [12]. However, due to D2 protein concentration
limitations mentioned above, another reason for no FRET could be from the fact that we set the
donor at ~ 5x (300 nM) of the Kd instead of 10x of Kd. We also used an acceptor at 13x (4096
nM) of donor concentration instead of 20x and these conditions maybe have not been ideal for
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the FGF to saturate the D2. Further optimization of these ensemble FRET parameters need to be
done in order to replicate the ITC experiments and extend to smFRET.

Conclusion
In conclusion, these preliminary results report that cysteine mutants of S3C-D2, E91CD2 and E56C-D2 of the D2 domain were successfully synthesized. The results also showed that
the refolding step of the denaturing purification protocol worked, since intrinsic fluorescence of
S3C-D2 was typical of globally folded protein. Further, S3C-D2 mutant was successfully labeled
with AF488 and AF546 with high labeling efficiency in order to act as donors during FRET with
FGF1. Although sFGF1 mutations were not to cysteine residues, it also labeled with high
efficiency because its conformational changes exposed the native cysteines to label which is
normally not the case with wt-FGF1. Ensemble FRET studies were not successful, and this could
be due to various factors such as loss of quantum yield and lack of strong electrostatic interaction
between the proteins, which all need to be investigated so that these studies can be extended to
smFRET. Overall, these preliminary results, will be building blocks for future work and further
development of this project. In addition, since FGF1 has been labeled with an array of dyes
spanning the visible light region of the spectrum from our previously submitted manuscript, this
will give the researcher options in choosing FGF1 to act either as a donor or acceptor in FRET
assays

Future work
Optimization of the Purification Protocol for D2 Domain
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The main hindrance to the progression of this project was due to the challenges of
overexpression and purification of the D2 mutants since they form inclusion bodies during
protein expression which are not soluble in aqueous mediums. These inclusion bodies need to be
solubilized by the use of high concentration of denaturing agents such as urea (8 M) which then
pose the second challenge of refolding the protein into its native form during or after
purification. The initial approach we used to purify D2 was to add a 6X His tag at the C terminal
so that a nickel affinity column and imidazole gradient in PBS buffer can be used for both
gradient elution and on-column refolding. However, the refolding steps caused aggregation
which then led to very low yields. To solve this problem, the Kumar group attached a Ruby tag
(Rd) under propriety to the D2-His-tag, and it prevented the formation of inclusion bodies as the
protein remained soluble during expression and therefore, could be purified without
denaturation. Although this method had high protein yield, the protein was not pure and required
heat treatment in order to get rid of impurities. Building on the preliminary purification results of
the Rd-D2-E56C mutant shown above, future work can focus on optimizing the heat treatment
step and efficiency of cleavage of the Rd tag by TEV, in order to obtain pure protein with high
yield. Further, the global folding will need to be analyzed as this will be critical to binding to
FGF during FRET assays.

Fluorescent labeling of the D2 Domain
Since the results showed that S3C-D2 mutant was successfully labeled with AF488 and
AF546, more fluorescent dyes from the rhodamine, cyanine or iFluor series can be explored for
labeling and evaluated for their photophysics behavior (e.g., lifetime, molecular brightness,
quantum yield) on the protein. This characterization of labeled D2 will be critical as factors such
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as dye structure, local environment and site of labeling will affect the usefulness of the protein
for FRET assays. From our previous work, we successfully labeled and characterized the
photophysics parameters of F2C-FGF1 and T79C-FGF1 mutants. Therefore, this work will give
a wide option of labeled FGF1 to choose from when doing FRET assays with labeled D2.
Further, these labeled FGF1 can also be useful in imaging studies of cell transfected with FGFR
labeled on the D2 domain during imaging studies. Fluorescently labeled sFGF1 with AF594 can
also be explored for labeling with other dyes and characterized, since it does not require site
specific mutagenesis.

Ensemble and Single molecule FRET assays between D2/FGF1
Our preliminary results of ensemble FRET assays between S3C-D2-AF488/F2C-FGF1AF594 S3C-D2-AF546/F2C-FGF1-AF647 were not successful. However once D2 domain has
been labeled and fully characterized in the future, FRET assays can be carried out since FGF1
has already been fully labeled and characterized with an array of dyes from our previous work.
We expect FRET to occur when the fluorescent dyes’ dipoles couple as the domains interact
within at least 100 Å. The partner labeled with the dye that has the highest absorption
wavelength will act as the donor while the one with the lowest absorption wavelength will be the
acceptor. The choice of proteins to act as either donor or acceptor can be based on which dyes
give the best labelling efficiency and their photophysics properties. Ensemble measurements will
provide mean properties of the various sub-populations and we expect a FRET curve to be
observed during fitting. Similar to the ITC results, in the absence of heparin, we will expect a
lower FRET efficiency at a given concentration, since these two domains are known to have
weak binding. However, in the presence of heparin, we will expect a higher FRET efficiency
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since heparin results in strong dimerization of FGF/D2 interactions. We expect FRET curve to be
improved by investigating factors such as ionic strength and pH, as we expect the dimerization
efficiency will be affected. Once the experiments are carried out at single molecule level, we
expect the subpopulations and heterogeneity to be revealed both in the absence and presence of
heparin.

smFRET assays to Study the Regulation of FGFR by Autoinhibitions
Autoinhibition is thought to be one of the mechanisms involved in regulation of FGFR
but there two conflicting models as to the sequence of events that lead to inhibition. One model
proposes that the AB swings to the heparin binding site (HBS) on D2 in order to prevent binding
of FGF to this domain. [26] The rationale behind this model is based on the fact that HBS on D2
is positively charged and therefore the negatively charged AB can bind to prevent heparin from
tightening the FGF/D2 interaction. Conversely, another model proposes that the AB binds the
positively charged FGF thus also preventing it from recruiting the D2 in order to trigger
dimerization. [27] A combination of ensemble techniques of surface plasmon resonance and
NMR supported the first model however, to the best of our knowledge, fluorescence resonance
energy transfer (FRET) has never been used to determine which model of FGFR autoinhibition is
correct. To settle the autoinhibition debate, we propose the use FRET to determine the binding
affinities between proposed partners in each model. High FRET exhibited by either one of the
models will be used as support for that model as this will indicate that indeed the proposed
domains are binding.
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V. Conclusion
The studies conducted in this body of work yielded insights into the ensemble and single
molecule photophysical characterization of fluorescently labeled hFGF1 for prospective use in
the design of smFRET assays between hFGF1 and FGFR. Firstly, these studies clearly showed
the significance of using chemical intuitiveness to carefully design mutants of globular protein
such as hFGF1 for fluorescent labeling, since labeling sites and dye structures greatly influence
the labeling efficiency of the dye, bioactivity of the protein and photophysical behavior of the
dyes. Secondly, the studies revealed that the ability to detect photophysical properties at the
ensemble or single molecule level, was dependent on the degree of flexibility of both the dye and
labeling sites and the local environment of the dye on the protein. Thirdly, this study showed that
D2 domain mutants could be fluorescently labeled if purification protocol can be optimized to
increase the protein yield. Moreover, preliminary ensemble FRET assays indicated that FRET
can be done between D2/FGF, with optimization of conditions such as ionic strength and careful
choice of dye FRET pairs in the future.
The three native cysteine of wildtype hFGF1 were found to not fluorescently label with
maleimide dyes hence the need to synthesis the cysteine mutants on hFGF1. Mutants of F2ChFGF1 and T79C-hFGF1 were successfully synthesized and found to not affect the global
folding of the protein although, there was some slight broadening compared to the wildtype.
F2C-hFGF1 is located on the flexible N terminal loop while T79C-hFGF1 is on the loop between
β strand 7 and 8. Fluorescent labeling of these sites by rigid rhodamine and flexible cyanine dyes
showed that a certain degree of flexibility of both the dye and protein is required for high
labeling efficiency however, too much flexibility decreased labeling due to entropic penalty
during labeling. In addition, since the labeling sites were far from the heparin and FGFR binding
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sites, these labeled mutants exhibited similar bioactivity relative to the wildtype. Hence, we
reported functional hFGF1 that is site specifically labeled with dyes that span the visible light
region of the electromagnetic spectrum for prospective use in in-vitro studies such as smFRET
assay.
Photophysical characterization of fluorescently labeled F2C-hFGF1 and T79C-hFGF1
revealed ensemble level (QY) and single molecule level (fluorescence lifetimes and molecular
brightness) parameters did not always correlate. This was due to the fact that the dye structure,
degree of flexibility of both the dye and labeling site and local environment of the dye on the
protein affected these parameters in unpredictable ways. For instance, the results showed that
although F2C position labeled with rigid rhodamine dyes was highly quenched in ensemble QY
relative to free dyes, at the single molecule level, its lifetime and molecular brightness were
similar to that of free dyes thus indicating high static quenching. Conversely, F2C labeled with
flexible cyanine dyes showed the opposite effect in that all ensemble and single molecule
parameters were greatly enhanced upon conjugation of the free dye to this position. T79C
labeled with these cyanine dyes also showed high increase in fluorescence compared to free dye
and even higher increase in the photophysics properties compared to F2C-hFGF1 labeled with
the same cyanine dyes. We detail the photophysics properties of these fluorescently labeled
hFGF1 as this information is critical in designing smFRET assays with FGFR and with other
hFGF1 binding proteins or drug ligands.
The preliminary attempted ensemble FRET assays between S3C-D2 domain and F2ChFGF1 were not successful however, with optimization such as changing the buffer ionic
strength, using heparin and choice of FRET dye pairs, it can be improved. The primary challenge
to developing FRET assays in this project was the low yield of D2 domain protein after
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purification. However, the D2 mutants of S3C and E91C were successfully synthesized using the
denaturation purification protocol and S3C was globally folded. In addition, the result showed
that the non-denaturing purification protocol that used the Ruby (Rd) tag attached to the E56CD2 mutant, could improve protein yield with further method optimization. Although FRET could
not be carried out, fluorescent labeling of S3C-D2 mutants with donor dyes of AF488 and AF546
was highly successful as well as fluorescent labeling of a non-cysteine mutant of superFGF1
with AF488 developed by the Kumar group. These overall preliminary results will be highly
useful towards designing FRET studies once the D2 mutants purification can be optimized,
labeled and charactered. Further, there will be an array of dyes of labeled hFGF1 to select from
since chapter 1 and 2 has thoroughly characterized fluorescently labeled hFGF1.
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